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ABSTRACT
Lupus nephritis (LN) is a chronic autoimmune-inflammatory condition that can lead to end-stage 
renal disease because of the breakage of immune self-tolerance occurring in systemic lupus 
erythematosus (SLE) patients. Presently available immunosuppressive treatments for LN are 
suboptimal and can induce significant side effects. We have recently characterized a novel 
immunomodulatory activity on the minor isoform of the classical pathway complement inhibitor, 
C4BP(-). We show here that C4BP(-) treatment prevented the development of proteinuria and 
albuminuria, decreased significantly the formation of anti-dsDNA antibodies and, locally, 
mitigated renal glomerular IgG and C3 deposition and generation of apoptotic cells, with the 
consequent histological improvement and increased survival in lupus-prone mice. The 
therapeutic efficacy of C4BP(-) was analogous to that of the broad-acting immunosuppressant 
cyclophosphamide (CYP). Remarkably, a comparative transcriptional profiling analysis revealed 
that: 1) the renal gene expression signature resulting from C4BP(-) treatment turned out to be 
10 times smaller than that induced by CYP treatment, and 2) C4BP(-) immunomodulation 
induced significant downregulation of LN relevant transcripts indicating immunopathogenic cell 
infiltration, including activated T cells (Lat), B cells (Cd19, Ms4a1, Tnfrsf13c), inflammatory 
phagocytes (Irf7) and neutrophils (Prtn3, S100a8, S100a9). Furthermore, cytokine profiling and 
immunohistochemistry confirmed that C4BP(-), through systemic and local CXCL13 
downregulation, was able to prevent ectopic lymphoid structures neogenesis in aged LN mice. 
Thus, because of its anti-inflammatory and immunomodulatory activities and high specificity, 
C4BP(-) could be considered for further clinical development in SLE patients.
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TRANSLATIONAL STATEMENT
Lupus nephritis (LN) is a chronic autoimmune-inflammatory condition for which current 
treatments with NSAIDs and immunosuppressive drugs, and even with new biologics, remain 
unsatisfactory and/or induce non-specific adverse events. Therefore, novel therapeutic agents are 
needed, with increased potency, selectivity and safety profiles. We have recently characterized a 
novel immunomodulatory activity in the minor isoform of the complement inhibitor C4BP(-). 
Here we show that this non-canonical activity limits the evolution of LN in lupus-prone mice, 
preventing the development of CXCL13-driven renal ectopic lymphoid structures. Thus, the anti-
inflammatory and tolerogenic functions of C4BP(-) might contribute significantly to restore 
immune homeostasis and to achieve better outcomes in LN management. 
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INTRODUCTION
Systemic lupus erythematosus (SLE) is heterogeneous in nature regarding organ 
involvement, clinical manifestations and severity, although the most life-threatening trait is 
progressive nephritis, leading to end-stage renal disease.1 A key early event in lupus nephritis 
(LN) involves impaired myeloid phagocytes which, unable to clear apoptotic cell debris and/or 
neutrophil extracellular traps (NETs), initiate a TLR-mediated pro-inflammatory program 
leading to direct activation of effector T cells and indirect activation of B cells through the 
production of important mediators such as B-cell activating factor (BAFF).2–4 In turn, stimulation 
and increased survival of B cells leads to the production of pathogenic autoantibodies against 
nuclear components (e.g., nucleic acids and histones), local parenchymal immune complex (IC) 
deposition and activation of the complement system, and additional production of pro-
inflammatory chemokines and cytokines such as IFN-I.5 These events induce a self-sustaining 
feed-forward loop of chronic inflammation and progressive glomerular, tubulointerstitial and 
endothelial kidney damage. In fact, focal infiltration and progressive organized aggregation of 
immune cells is the hallmark of autoreactive ectopic lymphoid structures (ELS), also known as 
tertiary lymphoid organs, developing in both human and murine LN.3,6 Thus, circulating and 
resident immune cells become important causative agents in the promotion of pro-inflammatory 
renal injury through ELS expansion, which maximizes the encounters between autoantigens, 
antigen-presenting cells and lymphocytes, important for the local initiation and maintenance of 
adaptive immune responses. This knowledge framework offers insight for the development of 
targeted immunotherapy interventions able to halt tissue damage and chronic inflammation by 
restoring operational immune tolerance. Accordingly, a new group of biologics, mostly 
neutralizing antibodies directed against pro-inflammatory molecular targets or cellular leukocyte 
subsets, such as rituximab, eculizumab, or belimumab, are on pre-clinical or early clinical 
development aiming to become efficient immunomodulatory agents without the unwanted effects 
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of broad-based immunosuppression displayed by conventional therapy, such as long-term 
toxicity by cyclophosphamide (CYP) and steroids. However, thus far the therapeutic benefit of 
biologics for inflammatory renal disease has been limited.7 
Synthesized mainly in the liver, C4b-binding protein (C4BP), a main regulator of the 
complement system, is relatively abundant in the circulation as a major heterooligomer (71, or 
C4BP(+)), and a minor homooligomer (70, or C4BP(-)) that becomes significantly 
upregulated under inflammatory conditions (e.g., acute phase response).8,9 Both isoforms are 
able to inhibit the classical and the lectin pathways of complement activation.10 In addition 
C4BP(+), through its -chain, forms a high-affinity complex with protein S (PS), which endows 
it with additional roles in coagulation and in apoptotic cell binding.11,12 Alternatively, we have 
recently described a novel anti-inflammatory and immunomodulatory activity of human 
C4BP(-) capable to induce a myeloid-derived suppressor cell (MDSC)-like phenotype through 
its direct action on monocyte-derived dendritic cells (Mo-DCs), an established model of 
inflammatory DCs.13 
In this study we aimed to assess the therapeutic potential of C4BP(-) in experimental 
autoimmune LN. We show that C4BP(-), but not C4BP(+), mitigates the development of renal 
pathology in lupus-prone NZBW F1 and MRL-lpr mice, preventing the neogenesis of 
autoreactive ELS, which hold a key role locally enhancing renal maladaptive immune response 
and chronic inflammation.
Page 5 of 121






























































For Peer Review Only
 Luque et al. (October 2019) KI-12-18-1865.R1
6
RESULTS  
C4BP(-) preserves renal function in lupus-prone NZBW F1 mice
As we previously reported,13 human C4BP(-) confers a semi-mature, anti-inflammatory 
phenotype to LPS-matured Mo-DCs from healthy individuals. Thus, we first sought to confirm 
the immunomodulatory activity of human C4BP(-) in a mouse background. C4BP(-) treatment 
prevented the upregulation of CD80 and CD86 co-stimulatory molecule expression by cultured 
bone marrow-derived DCs stimulated with the TLR7 agonist gardiquimod, of relevance in LN 
pathology.14 (Supplementary Figure S1).
To assess the therapeutic potential of C4BP(-) in experimental autoimmune LN we 
designed an intraperitoneal administration schedule for this human plasma-purified protein into 
lupus-prone NZBW F1 mice (Figure 1a). Proteinuria is the most prominent and life-threatening 
sign in LN mice. It reflects renal dysfunction and closely correlates with disease outcome. In 
PBS vehicle-treated control mice, proteinuria started to develop at week 28 and progressed 
exponentially to severe proteinuria (> 300 mg/kg) by week 34 (8.5 months of age) up to the end 
of the study (week 36). In comparison, the onset of proteinuria was delayed until the end of the 
study by C4BP(-) treatment, and was significantly reduced from that of the control PBS 
vehicle-treated group (p<0.0001) (Figure 1b). Thus, neither the standard CYP treatment group 
nor the C4BP(-) treatment group did develop noteworthy proteinuria over time. Nonetheless, a 
slight upturn in proteinuria, particularly evident as microalbuminuria, appeared by week 36 in 
the C4BP(-) treatment group, compared with the CYP treatment group (Figure 1c). This 
apparently decreased therapeutic efficacy of C4BP(-) at later stages of treatment could reflect 
accelerated clearance due to the development of an immune xenoresponse against the 
administered human protein in the NZBW F1 immunocompetent mice.15 Certainly, repeated 
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C4BP(-) administration induced the production of anti-C4BP(-)-specific antibodies that were 
detected in the sera of the treated animals, peaking around week 32 (Supplementary Figure S2). 
In an additional set of experiments, we confirmed that as little as 50 g/mouse of purified 
C4BP(-) produced in HEK293 mammalian cells, administered biweekly and subcutaneously, 
was still able to ameliorate the renal function and increase the survival of nephritic NZBW F1 
mice, despite the comparable immunogenicity of both plasma-purified and recombinant C4BP(-
) (Supplementary Figure S3).
C4BP(-) attenuates the development of anti-dsDNA antibodies and ameliorates histologic 
damage in the kidneys of lupus-prone NZBW F1 mice
The autoantibody titers directly reflect autoimmunity status. In the vehicle PBS-instilled 
control NZBW F1 mice, the serum anti-dsDNA total Igs began to progressively increase at 5-6 
months of age (week 20-24). Within another 3 months the anti-dsDNA Igs reached its highest 
titer, which persisted thereafter (Figure 2a). In comparison, mice from the C4BP(-) group had a 
sustained lower level of autoantibodies throughout the analysis period (weeks 28 to 36) (p<0.05). 
As expected, the standard CYP treatment group also showed reduced anti-dsDNA autoantibody 
levels.
Even though proteinuria reflects the severity of renal dysfunction, the pathological study 
directly reveals tissue damage in LN. Common characteristics of severe nephritis in lupus 
kidneys include proliferative changes in the mesangial and endothelial cells of the glomeruli, 
capillary basement membrane thickening, severe interstitial infiltrates, tubular atrophy and large 
protein casts. Figure 2b-d compares representative renal histologic findings in the C4BP(-) and 
CYP treatment groups and in the PBS vehicle control group. The 9-month old control PBS mice 
exhibited typical nephritis changes, including significantly enlarged and hypercellular glomeruli 
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(Figure 2c), interstitial inflammation and widespread proteinaceous tubular casts, as expected 
from their severe proteinuria. Conversely, age-matched mice in both the C4BP(-) and CYP 
treatment groups presented almost intact glomeruli, tubules and interstitium, with lower 
pathologic scores (Figure 2b-d). Thus, C4BP(-) treatment attenuated the development of anti-
dsDNA antibodies, protecting kidneys from autoantibody induced damage. 
Renal IC deposits and apoptotic cells are significantly reduced in C4BP(-)-treated lupus-
prone NZBW F1 mice
  
IC deposits in the kidneys provide direct evidence for the pathogenicity of the 
autoantibodies in the target organ and are associated with nephritis in NZBW F1 mice.16 We 
stained renal cryosections for IgG and C3, two major components in IC. In the vehicle-treated 
PBS control mice, there was pronounced IgG and C3 deposition in the glomeruli (Figure 3a) 
which was markedly diminished both in C4BP(-)-treated and in CYP-treated mice (p<0.0001). 
Therefore, the IC deposits were consistent with the renal histopathological changes. 
Impaired clearance of apoptotic debris and IgG ICs by phagocytes is considered to be one 
of the main causes of inflammation associated with LN.17 Indeed, TUNEL analysis revealed 
widespread presence of both intraglomerular and extraglomerular apoptotic cells in the kidneys 
of PBS-treated mice. In contrast, both C4BP(-)- and CYP-treated mice had essentially no 
apoptotic cells in the renal cortex  (Figure 3b), correlating with reduced kidney damage.
C4BP(-) targets molecular/cellular hallmarks of  LN 
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To gain further insight into the local immunomodulatory events induced by C4BP(-) 
treatment at the molecular and cellular level, we performed a comparative transcriptional 
profiling of renal tissue from C4BP(-)-treated, CYP-treated, and PBS-treated control NZBW F1 
mice. The in-house designed array included 377 genes involved in SLE pathology 
(Supplementary Table S1). Remarkably, an initial evaluation of the expression profiles of 
C4BP(-)-treated and CYP-treated mice, both relative to PBS-treated control mice, unveiled a 
drastically different appearance in their overall shape  (Figure 4a). Accordingly, only 24 
differentially expressed transcripts (FC > 1.8) were apparent between the C4BP(-)-treated and 
the PBS-treated kidneys (Supplementary Table S2). Conversely, the same analysis when 
comparing CYP-treated and PBS-treated kidneys yielded 224 differentially regulated transcripts 
(Supplementary Table S3). Taking into account the comparable therapeutic efficacies of 
C4BP(-) and CYP treatments in LN mice, as perceived from the previously analyzed 
parameters, this outcome suggests more specific immunomodulation induced by C4BP(-) over 
the immunosuppressant CYP in LN NZBW F1 mice. 
An additional gene-interaction based bioinformatics analysis of the analyzed genes 
revealed that relevant biological functions modulated by C4BP(-)-treatment involved reduced 
renal leukocyte migration, particularly of myeloid cells, and consequently, a decreased quantity 
and activation of infiltrated mononuclear leukocytes, predominantly B lymphocytes 
(Supplementary Table S4). Conversely, a great number of additional relevant pathways, such 
as the complement pathway, were appreciably regulated only by CYP treatment (data not shown) 
suggesting increased toxicity of the immunosuppressant CYP over C4BP(-).
Next, we validated the above results obtained with the microfluidics cards by analyzing 
renal tissue from individual mice within each group by RT-qPCR, and interrogating the 
transcripts that showed differential regulation by C4BP(-) at FC > 2.0 in the array. We 
confirmed significant differential C4BP(-)-mediated downregulation of 8 transcripts: Irf7, Lat, 
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Cd19, Ms4a1 (Cd20), Tnfrsf13c (BAFFR), Prtn3, S100a8 and S100a9 (Figure 4b). All but 
S100a8 and S100a9, encoding the S100a8/S100a9 complex calprotectin involved in 
inflammasome activation and myelopoiesis induction, were found also significantly 
downregulated by CYP treatment. Strikingly, while Irf7 is a key transcription factor involved in 
the type I IFN pathway activated by innate sensors, such as TLR7/8, as a consequence of 
impaired lysosomal maturation of SLE phagocytes,2 all other transcripts are cellular markers 
specific for activated T lymphocytes (Lat), B lymphocytes (Cd19, Ms4a1, Tnfrsf13c), and 
neutrophils (Prtn3, S100a8, S100a9). This again indicates significant leukocyte infiltration, 
suggesting a lack of immune tolerance as the underlying cause of LN pathology in the kidneys of 
PBS-treated control NZBW F1 mice which, however, could be mitigated by both C4BP(-) and 
standard CYP treatment. Further, assessment of network crosstalk between the C4BP(-) gene 
set including the above 8 significantly regulated genes and the KEGG pathways using PathwAX 
reflected significant (FDR < 0.05) depletion of immune hematopoietic cells and, particularly, of 
the B cell signaling and the pro-inflammatory NF-B pathways in C4BP(-)-treated renal tissue 
compared with the PBS-treated, nephritic tissue (Table 1).
C4BP(-) modulates the cytokine signature of lupus-prone NZBW F1 mice
To complement the transcriptional profiling results obtained, we examined the presence 
of inflammatory cytokines in the sera of the treated NZBW F1 mice at the end of the study.  
Remarkably, a cytokine array including 40 mouse cytokines, chemokines and acute phase 
proteins evidenced CXCL13 as the unique cytokine differentially abundant, present in PBS-
treated mice but absent in C4BP(-)-treated or CYP-treated mice (Figure 5a). This homeostatic 
B cell-attracting chemokine, produced by macrophages and dendritic cells, is extremely relevant 
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in SLE renal pathology. We confirmed the array findings assessing the CXCL13 levels in the 
sera of individual mice through a specific ELISA assay (Figure 5b).
An identical cytokine analysis, using renal tissue extracts instead of sera, endorsed 
differential expression of CXCL13 and, additionally, revealed local presence of the C5/C5a 
complement components, and of the IL1 family members IL1 receptor antagonist (IL1ra; IL-
1F3) and IL1 (Figure 5c and 5d). Thus, local increase of these inflammatory factors, while 
apparent in PBS-treated kidneys, could be prevented by C4BP(-) or CYP treatment. 
C4BP(-) treatment prevents leukocyte infiltration and the development of ELS in the 
renal parenchyma of lupus-prone NZBW F1 mice
LN, a chronic inflammatory condition, features significant leukocyte infiltration over 
time, as suggested by our transcriptional profiling data. Indeed, a thorough immunohistochemical 
examination regarding the presence of inflammatory leukocyte markers in the renal cortex of 36 
weeks old PBS-treated NZBW F1 mice evidenced positive staining, mainly perivascular and, 
occasionally, periglomerular, not only for activated T cells (Lat) and B cells (CD19), but also for 
different myeloid cell populations: neutrophils (Gr1), interstitial monocytes/macrophages 
(F4/80), and dendritic cells (CD11c). In contrast, the above markers were barely present (F4/80) 
or virtually absent in both C4BP(-)-treated or CYP-treated mice (Figure 6). 
The chemokine CXCL13 holds a key role recruiting and organizing nodular aggregates of 
B cells, activated T cells and DCs surrounded by neo-lymphatic vessels termed ELS.18 Indeed, 
we confirmed the presence of multiple ELS in the cortex of PBS-treated NZBW F1 nephritic 
mice by hematoxilin and eosin staining and by T cell (Lat) and B cell (Cd19) immunostaining 
(Figure 7). In contrast, C4BP(-) immunomodulatory activity prevented the development of 
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local inflammatory ELS in these mice, which correlated with reduced autoantibody anti-dsDNA 
formation and renal function improvement. 
The complement inhibitory activity of C4BP does not affect LN pathology in lupus-prone 
NZBW F1 mice
To assess whether C4BP-mediated complement inhibition could be responsible for the 
improvement of LN we performed a comparative study administering equal amounts of either 
the minor C4BP(-) isoform, sustaining both complement inhibitory and immunomodulatory 
activities, or the major isoform C4BP(+), holding only the complement inhibitory but not the 
immunomodulatory activity,13 into NZBW F1 mice. C4BP(-)-treated mice showed reduced 
proteinuria, decreased anti ds-DNA and blood urea nitrogen (BUN) levels, improved renal 
histology with minimal immune cell infiltration and a higher survival rate when compared with 
C4BP(+)-treated mice (Supplementary Figure S4). Furthermore, we analyzed the activity of 
the classical pathway of complement in fresh serum extracted from NZBW F1 mice previously 
(week 21), and at several points during C4BP treatment (weeks 25, 29 and 33). The complement 
activity was nearly within the normal range in young mice, before starting C4BP treatment, but 
was concomitantly reduced with the progression of LN pathology in both the PBS- and 
C4BP(+)-treated mice (Supplementary Figure S5). A severe drop in hemolytic complement in 
advance of clinical renal disease has been reported in these mice, which suggested consumption 
by ICs.19 In contrast, C4BP(-) treatment significantly precluded hypocomplementemia at the 
early stages of treatment. Nevertheless, complement exhaustion could not be prevented at the 
later stages of treatment, possibly due to lack of C4BP(-) immunomodulatory efficacy because 
of the development of the anti-human C4BP(-) immune xenoresponse, as previously indicated. 
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Therapeutic efficacy of C4BP(-) in lupus-prone MRL-lpr mice
We substantiated the above results and the overall therapeutic efficacy of C4BP(-) 
immunomodulation using MRL-lpr mice as an alternative spontaneous LN model.  Thus, a 
weekly treatment schedule using 100 g C4BP(-)/mouse starting at 10 weeks of age not only 
mitigated the development of proteinuria, increased survival, preserved renal histology 
preventing ectopic lymphoid tissue formation and increased the survival rate, but also 
ameliorated dermatitis and vasculitis, other SLE pathological traits developing in the MRL-lpr 
model (Figure 8).
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DISCUSSION
In this report we demonstrate the benefit of human C4BP(-), an acute phase protein with 
a well-known complement inhibitory function and with a previously unrecognized and recently 
characterized anti-inflammatory and tolerogenic activity towards inflammatory DCs, in two 
spontaneous models of autoimmune LN: NZBW F1 and MRL-lpr mice. A prior study has 
reported the potential of human C4BP(-) inhibiting the development of autoimmune arthritis in 
mice, which was exclusively attributed to its complement inhibitory activity.20 However, the fast 
systemic clearance of human C4BP(-) when administered to mice 20 suggests that an alternative 
mode of action of C4BP(-) might contribute significantly to the substantial therapeutic effect 
noticed in the arthritis models employed. In fact, we show here that the major C4BP(+) 
isoform, holding the same complement inhibitory activity than C4BP(-) but lacking 
immunomodulatory activity, 13 does not affect the development of LN from NZBW F1 mice. 
Furthermore, C4BP(-), but not C4BP(+), was able to prevent in these mice the progress to 
hypocomplementemia, an important marker for the presence of IC-mediated disease. It has been 
shown that complement titers fall significantly with renal disease progression, concomitantly 
with the appearance of anti-DNA autoantibodies in serum and of C3 Igs in renal glomeruli.19 
Nonetheless, we acknowledge C4BP(-) action limiting both C3 deposition in the glomeruli and 
the presence of C5/C5a in the renal cortex of C4BP(-)-treated NZBW F1 mice. In fact, 
inhibition of complement activity at different points, such as through mAb-mediated C5 
blockade,21 using C3a22 or C5a23 receptor antagonists, or by CR2-targeted complement 
inhibitors: CR2-DAF,24 CR2-Crry,25 or CR2-FH26 has proven useful in the amelioration of LN. 
Yet the deposition of ICs or complement does not seem sufficient for renal pathology.27–29 In our 
study, while CYP, a broad-acting immunosuppressant and standard of care treatment for the 
most severe manifestations of SLE,30 induced transcriptional downregulation of several 
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complement effectors in renal tissue from NZBW F1 mice, no such modulation was observed 
upon C4BP(-) treatment. Nevertheless, the therapeutic efficiency of C4BP(-) was comparable 
to that exhibited by CYP. Moreover, scaling down 10-fold the subcutaneous dosage of C4BP(-) 
to 50 g/mouse and setting up a bi-weekly administration schedule, was still able to significantly 
ameliorate disease severity in LN mice. 
Mouse C4BP lacks both the -chain,31 and two complement control protein domains 
(CCPs) in the -chain homologous to CCP5 and CCP6 from the human C4BP -chain.32 We 
have previously described that CCP6 is necessary for the immunomodulatory activity of human 
C4BP(-).13 Hence, the mouse constitutes a suitable animal model to assess the 
immunomodulatory activity of human C4BP(-) without interference from endogenous mouse 
C4BP.  Certainly, C4BP knock-out did not develop any autoimmune phenotype, and did not 
modify disease severity in MRL-lpr LN mice,33 stressing the relevance of human C4BP(-) 
immunomodulation in NZBW F1 LN pathology.  
Both C4BP(-),13 and the major alternative pathway complement inhibitor FH,34 through 
as yet unknown receptor(s), directly counteract cellular immune-inflammatory activation by 
inducing an anti-inflammatory and tolerogenic state on monocyte-derived DCs analogous to that 
recently described for monocytic MDSCs, which confer suppressive activity toward multiple 
myeloid and lymphoid cell subsets.35,36 Remarkably, myeloid cells seem to take a central 
pathogenic role in SLE owing to inefficient clearance of apoptotic cell debris and autoantigen-
autoantibody ICs by phagocytes because of defects in lysosomal maturation.2 Thus, FcRI-
mediated activation of DC and macrophage innate sensors, through accumulated IgG-ICs in their 
surfaces, seems to occur prior to significant B cell expansion, IFN- and BAFF secretion, and 
LN progression.17 For example, RNA sensing by conventional DCs through TLR7 has been 
reported to be critical to the development of LN.37 C4BP(-) is able to prevent TLR4- and 
TLR7-mediated activation of monocyte-derived DCs (13, and data not shown). Accordingly, 
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immunomodulatory C4BP(-) administration in our NZBW F1 LN model seemed to preclude 
glomerular and interstitial apoptotic cell accumulation and/or apoptotic debris coating of myeloid 
cells, either preventing cell dying or increasing their renal clearance. 
Strikingly, at the molecular level, a comparative analysis of the transcriptional 
fingerprints of C4BP(-), CYP, and the vehicle PBS induced in renal tissue from  36-week old 
NZBW F1 mice uncovered the high specificity of C4BP(-) treatment respect to the standard 
CYP regimen. Thus, setting the threshold FC to + 1.8, only 24 transcripts (6.4 % of the SLE 
genes arrayed) were regulated by C4BP(-) compared with 224 transcripts (59.4 % of the SLE 
genes arrayed) by CYP, nevertheless both conferring analogous functional improvements in the 
LN NZBW F1 kidneys. This points out to increased safety due to a much more focused and 
specific action of C4BP(-)-mediated immunomodulation as compared with the known toxicity 
profile concomitant to CYP global immunosuppression.  
The resulting C4BP(-) transcriptional profile also revealed exclusive downregulation of 
typical immune cell markers, with a significant reduction of B cell (Cd19, Cd20, BAFFR), T cell 
(Lat) and neutrophil (Prtn3, S100a8, S100a9) transcripts identifying inflammatory cell infiltrates 
in the renal parenchyma, relative to untreated nephritic NZBW F1 kidneys. Of note, the alarmin 
calprotectin (S100a8/S100a9), exclusively downregulated by C4BP(-) treatment, induces 
inflammasome activation and IL-1-dependent monocytosis and neutrophilia.38 Concordantly, it 
has been recently shown that human C4BP inhibits pancreatic islet amyloid polypeptide (IAPP)-
induced inflammasome activation.39 Indeed, the reduction/absence of both lymphoid and 
myeloid cells in C4BP(-)-treated kidneys was backed by immunohistochemical evaluation and 
confirms that C4BP(-) immunomodulation targets cellular effectors responsible for the immune 
dysregulation driving SLE.40 Moreover, experimental and bioinformatics analyses stressed the 
inhibition of the pro-inflammatory NF-kB and interferon (Irf7) pathways through C4BP(-) 
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action, leading to suppression of innate immune responses. Both pathways have deemed essential 
for autoantibody production and development of nephritis in murine lupus.41
Chronic, unresolved inflammation in LN paves the way for ELS development, a hallmark 
of tissue autoimmunity, which intends to address high local concentration of autoantigens 
supporting the formation of a network of follicular DCs (FDCs) for antigen presentation, 
surrounded by proliferating/activated B- and T-cell rich areas, much like secondary lymphoid 
organs. It has been shown both in the NZBW F1 model and in LN patients that the chemokine 
CXCL13 plays an important role in the initiation and development of LN,42,43 and abnormally 
increased serum CXCL13 levels could induce extensive chemotaxis of CXCR5-expressing B 
cells, activated T cells and DCs into renal LN tissues stimulating inflammatory ELS 
formation.18,44 Conversely, it has been shown that direct CXCL13 blockade disrupts ELS 
formation45 and attenuates LN in MRL-lpr mice.46 Remarkably, C4BP(-) treatment leads also to 
significant CXCL13 downregulation both systemically and locally in NZBW F1 kidneys. 
Consequently, the presence of cortical ELS in our C4BP(-)-treated aged mice was virtually 
absent, consistent with substantially reduced inflammatory immune cell infiltrates  compared 
with untreated nephritic aged mice. FDCs have been considered the main producers of CXCL13, 
although newly recruited monocytes, macrophages and myeloid DCs have also been shown to 
secrete CXCL13 in response to activation by TLR2/4 ligands.47–51 Thus, C4BP(-) action 
through the inflammatory myeloid cell-CXCL13-ELS axis would prevent ELS neogenesis in 
chronically inflamed tissues, which has been correlated with allograft rejection and autoimmune 
disease progression.52 
In summary, additional studies will be required to further decipher the molecular 
mechanism of C4BP(-) immunomodulation leading to improvement of LN pathology. 
Nevertheless, the relevant efficacy and specificity of C4BP(-) in both NZBW F1 and MRL-lpr 
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LN mice anticipates promising possibilities to explore novel therapeutic options for LN SLE 
patients.  
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Peripheral blood from healthy individuals was supplied by the local blood bank. The 
C4BP(+) heterooligomer was purified from pooled plasma by BaCl2 precipitation, as previously 
described.53 C4BP(-) was obtained from pooled plasma supernatants after BaCl2 precipitation, 
and purified according to a protocol set up from Bioingenium (Barcelona, Spain). Their purity 
was higher than 85%, as assessed by SDS-PAGE and Coomassie Blue staining (Supplementary 
Figure S6). CYP (Genoxal®, Baxter Oncology GmbH, Halle/Westfallem, Germany), was 
resuspended in saline. Further information is given in Supplementary Methods. 
Mice, study design and follow up
We used NZBW F1 and MRL-lpr female mice 54 (Jackson Laboratory, Bar Harbor, ME, 
USA) (6 - 8 animals/group), aged 6 months (NZBW F1 mice; 35-40 g/each) or 2.5 months 
(MRL-lpr mice; 25-30 g/each), for the studies. C4BP isoforms (C4BP(-), rC4BP(-), and 
C4BP(+)) were administered intraperitoneally (ip) or subcutaneously (sc), as indicated, for 3 
months (between 6 and 9 months of age in the case of NZBW F1 mice, and between 2.5 and 5.5 
months of age in the case of MRL-lpr mice), at the specified doses and schedules. CYP was also 
administered ip at 2.5 mg/mouse every 10 days, in the same timeframes, as previously 
described.55,56 Finally, a control group underwent vehicle PBS administration following the same 
administration route and schedule as the C4BP(-) group in the different studies (Figures 1a and 
8a; Supplementary Figures S3a and S4a). Detailed procedures are given in Supplementary 
Methods.
Renal function analysis: proteinuria, albuminuria and BUN
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Twenty-four hour urinary protein was determined by the pyrogallol red-molibdate 
protein-dye binding method (Olympum Autoanalyzer AU400, Hamburg, Germany) while 24 h 
urinary albumin was determined using a commercially available ELISA KIT (Active motif, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. 
Levels of BUN in the sera from the NZBW F1 mice were measured using a commercially 
available enzymatic kit (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s 
recommendations.
Assessment of anti-dsDNA antibodies
Levels of anti-dsDNA antibodies (IgG + IgA + IgM) were measured using a 
commercially available ELISA kit (Alpha Diagnostic International, San Antonio, TX, USA) 
according to the manufacturer’s recommendations. 
Renal histopathology
Coronal kidney slices (1–2 mm thick) were fixed in 4% paraformaldehyde and embedded 
in paraffin. For light microscopy, 5 m thick tissue sections were stained with hematoxylin and 
eosin (H&E) and analyzed in a Nikon Eclipse 80i microscope (Nikon Instruments, Amstelveen, 
Netherlands). Glomerular cross-sectional area (µm2) was calculated based on average area of 
150 glomeruli in each group. Details are given in Supplementary Methods. 
Immunofluorescent determination of renal IC and complement deposition
For analysis of IgG and C3 deposition, fluorescent staining of kidney cryo-sections was 
performed. Sections were directly stained with fluorescein isothiocyanate (FITC)-conjugated 
goat anti-mouse IgG (Sigma-Aldrich), and FITC-conjugated C3 (Nordic Immunology, Tilburg, 
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The Netherlands). At least 10 glomeruli per section were visualized. For detailed analyses, see 
Supplementary Methods.
Complement activity assay
Activity of the classical complement pathway in fresh sera was determined by C3b 
deposition on K562 cells opsonized with rabbit polyclonal antibodies (Agrisera, Vännäs, 
Sweden), as previously described,20 and quantified using FITC-conjugated goat IgG fraction to 
mouse complement C3 antibody (MP Biomedicals, Solon, OH, USA) and flow cytometry. Heat-
inactivated serum samples (56 ºC, 30 min) were used as negative controls. A further description 
is given in Supplementary Methods.
Immunohistochemistry
The following primary antibodies were used: polyclonal rabbit anti-mouse CD11c (1:200, 
Biorbyt, BioNova, Cambridge, UK), polyclonal rabbit anti-mouse Lat (1:50, ThermoFisher, 
Waltham, MA, USA), monoclonal rat anti-mouse Gr1 (1:50, R&D Systems, Minneapolis, MN, 
USA), monoclonal rat anti-mouse F4/80 (1:50, ThermoFischer), monoclonal rat anti-mouse 
CD19 (1:200, ThermoFischer). F4/80 marker detection required antigen retrieval using 
proteinase K. After PBS washing, slices were incubated with the appropriate secondary antibody: 
biotinylated goat anti-rabbit IgG (1:200, Vector laboratories, Peterborough, UK), or 
ImmPRESS™ HRP anti-rat IgG (mouse adsorbed) polymer detection kit (Vector laboratories) 
for 1 h at RT. Regarding CD11c and Lat markers, standard Vectastain (ABC) avidin-biotin 
peroxidase complex (Vector laboratories) was applied. For further details about tissue processing 
and staining, see Supplementary Methods. 
TUNEL Assay
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Apoptosis detection was performed by terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling (TUNEL) using the “TACS TdT in situ DAB” kit (R&D Systems) 
according to the manufacturer's instructions. Details are given in Supplementary Methods.
Differential gene expression analysis
Total RNA from mouse kidneys was extracted using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany). Gene expression profiling was performed by interrogating reverse transcribed 
pooled cDNA (2-3 animals/group) using custom TaqMan Low Density Arrays (TLDA Cards) 
(Applied Biosystems, Carlsbad, CA, USA) (Supplementary Table S1) run on the 7900HT 
system for quantitative real-time PCR analysis according to the manufacturer’s instructions. 
Differentially expressed genes were analyzed using the Ingenuity Pathway Analysis (IPA) 
(Ingenuity Systems, Qiagen) to identify biological and molecular networks differentially 
regulated in the LN model. Selected gene transcripts were further validated in individual mouse 
kidney samples by RT-qPCR using TaqMan Gene Expression Assays (Applied BioSystems). 
Pathway annotation of the RT-qPCR-validated gene set was performed through PathwAX.57 
Detailed procedures are given in Supplementary Methods.
Mouse cytokine array
Serum and renal lysates were analyzed using the Proteome Profiler Array “Mouse 
Cytokine Array Panel A” kit (R&D Systems), according to the manufacturer’s instructions. 
Further details are given in Supplementary Methods.
CXCL13 ELISA
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CXCL13 cytokine levels from both sera and tissue lysates were quantified using the 
“Legend Max Mouse CXCL13 (BLC) ELISA” kit (BioLegend, San Diego, CA, USA) according 
to the manufacturers’ instructions.
Statistical analysis 
Statistical analyses and scientific graphing were performed using the GraphPad Prism 6 
software (GraphPad software, Inc, La Jolla, CA, USA). Two-way ANOVA, corrected for 
multiple comparisons using the Holm-Sidak method, was applied to analyze proteinuria, 
albuminuria, BUN, anti-dsDNA antibodies, complement activity and dermatitis scores 
throughout the follow up studies. One-way ANOVA, corrected for multiple comparisons using 
the Dunnett’s method, was employed to assess histological data and CXCL13 cytokine levels. 
Meier plots along with the log-rank (Mantel-Cox) test were performed to assess the differences 
in the survival distributions. Vehicle PBS-treated mice were assigned as the reference group, 
unless otherwise indicated. Relative gene expression levels between the C4BP(-)- and CYP-
treatment groups relative to the vehicle PBS-treated group in the validation step were analyzed 
using the one sample t-test. The Friedman test, corrected using the Dunn’s post-hoc analysis 
method, was applied to compare flow cytometry (MFI) data. Unless otherwise stated, data are 
expressed as mean values + SD. In all cases, a P value < 0.05 was considered significant. 
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Table S1. List of relevant SLE genes included in the customized TaqMan Low Density 
Array.
Table S2. List of genes induced by C4BP(-) treatment (FC > 1.8).
Table S3. List of genes induced by CYP treatment (FC > 1.8).
Table S4. Relevant enriched biological functions (IPA®) associated with differentially 
expressed renal genes from C4BP(-)-treated NZBW F1 mice
Supplementary Methods.
Supplementary material is linked to the online version of the paper at www.kidney-
international.org.
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FIGURE CAPTIONS 
Figure 1.- Renal function determination in lupus-prone NZBW F1 mice.
Schematic administration schedule and dosage for intraperitoneal (ip) injection of C4BP(-) and 
vehicle (PBS) (blue arrows), and cyclophosphamide (CYP) (red arrows) in lupus-prone NZBW 
F1 mice (a). Proteinuria and albuminuria were monitored monthly over the course of the assay 
and all animals were sacrificed at week 36 (w36). Total 24-h urinary protein was determined by 
Pyrogallol Red-molybdate protein dye-binding assay (b), and 24-h urinary albumin was 
determined by ELISA (c) as described in Methods. Data are normalized by mouse weight and 
expressed as mean values + SD (n= 4-8 mice/group); ***p < 0.001; ****p < 0.000,1 compared 
with control, PBS-treated mice.
Figure 2.- Anti-dsDNA autoantibody production and renal histology assessment in lupus-
prone NZBW F1 mice.
(a) Serum levels of anti-dsDNA antibodies correlating with disease activity were measured by 
ELISA from week 20 (pretreatment) to week 36. Data are expressed as mean + SD (n= 7 
mice/group); *p < 0.05; **p <0.01; ****p <0.0001, compared with vehicle PBS-treated mice. 
(b) Representative sections of renal cortex from 36-week old NZBW F1 mice treated with CYP 
(left), C4BP(-) (center) and vehicle PBS (right) mice stained with hematoxylin and eosin. 
Images are shown at low (upper panels; scale bars: 200 m) and high (lower panels; scale bars: 
50 m) magnification. The data obtained were used to comparatively evaluate the glomeruli area 
(c) and to semi-quantitatively grade histopathology traits indicating active LN (mesangial 
expansion, endocapillary proliferation, glomerular deposits, extracapillary proliferation and 
interstitial infiltrates), as well as chronic lesions (tubular atrophy and interstitial fibrosis) (d). 
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Figure 3.- Immunohistochemical analysis of IgG and C3 deposits and evaluation of 
apoptosis in the renal cortex of lupus-prone NZBW F1 mice.
For analysis of local IgG and C3 deposition, fluorescent staining of renal cryo-sections was 
performed (a). Representative fluorescent images from IgG- and C3-stained vehicle PBS- and 
C4BP(-)-treated NZBW F1 mice are shown (scale bar: 50 m) (upper panels). Fluorescence 
was expressed as mean fluorescence intensity (MFI) + SD (n= 7 mice/group); ****p < 0.0001, 
compared with vehicle PBS mice (lower panels). Apoptosis in the renal cortex was detected by 
TUNEL assay (b). Representative images from renal cortex of CYP-, C4BP(-)-, and PBS 
vehicle-treated NZBW F1 mice are shown at low (scale bar: 200 m) and high (scale bar: 50 
m) magnification. Scoring of cortical apoptotic cells as cell number per field (left graph) and 
glomerular apoptotic cells as cell number per glomerular cut section (gcs) (right graph). Data are 
expressed as mean + SD (n= 3 mice/group); ****p <0.0001, compared with vehicle PBS-treated 
mice. 
Figure 4.- Comparative transcriptional profiling of renal tissue from lupus-prone NZBW 
F1 mice.
Overall comparative transcriptional profiles of 36-week renal tissue from CYP- and C4BP(-)-
treated mice relative to the 36-week nephritic transcriptional profile displayed by renal tissue 
from vehicle PBS-treated mice (a). Total renal RNA was interrogated against a panel of 377 
murine genes relevant in LN pathology. Gene expression data are given as Log2FC (FC, fold 
change). The discontinuous horizontal lines indicate a fold change threshold of + 1.8 for 
upregulated and downregulated genes. TaqMan RT-qPCR individual validation of all genes 
showing a FC induction > 2 in the C4BP(-) transcriptional profile (b). Relative expression data 
for the specified genes was obtained from renal RNA of individual mice belonging to each 
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treatment group (n= 3-5 mice/group). Log2FC values are expressed as mean + SD; *p <0.05, **p 
<0.01 compared with vehicle PBS-treated mice.
Figure 5.- Circulating and renal cytokine profile from lupus-prone NZBW F1 mice.
Sera (a) and renal tissue extracts (c) were incubated with the R&D Systems “Proteome Profiler 
Mouse Cytokine Array Kit”, according to the manufacturer’s guidelines. The density of each dot 
was quantified with Quantity One® software and displayed as normalized mean pixel density for 
each relevant cytokine and treatment. Additional validation of the chemokine CXCL13 was 
performed in individual mouse samples (n= 4 mice/group) by a specific ELISA (b and d). Data 
are expressed as mean values + SD; ****p <0.0001, compared with vehicle PBS-treated mice.
Figure 6.- Immunohistochemistry of renal cortex from lupus-prone NZBW F1 mice.
Assessment of immune cell infiltrates in renal cortex sections from CYP-, C4BP (-)-, and 
vehicle PBS-treated aged NZBW F1 mice at the end of the study (36 weeks old). Local intense 
perivascular, periglomerular and/or glomerular staining was observed in vehicle PBS-treated 
kidneys surveyed for activated T cells (Lat), B cells (CD19), and myeloid cells such as 
neutrophils (Gr1), DCs (CD11c), and monocytes/macrophages (F4/80), the latter presenting a 
strong and diffuse periglomerular staining (lower panels). Conversely, CYP-treated (upper 
panels) and C4BP(-)-treated (middle panels) kidneys were found scarcely stained for the above-
referred inflammatory markers. Scale bars: 50 m. Results from each panel are representative of 
staining performed on tissue from 3 animals in each group.
Figure 7.- C4BP(-) treatment prevents the development of ELS in lupus-prone NZBW F1 
mice.
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Upper panels, low resolution hematoxilin-eosin stained representative renal cortex sections from 
C4BP(-)-treated (left) and vehicle PBS-treated (right) aged (36 week old) NZBW F1 mice. ELS 
are clearly visible in the PBS-treated mice (black arrows), but absent in C4BP(-)-treated mice. 
Scale bars: 200 m (representative images from 4 mice/group). Lower panels, consecutive renal 
sections of C4BP(-)-treated and PBS-treated mice stained with hematoxilin-eosin (left), and 
immunostained with Lat (activated T cell marker) (center) and CD19 (B cell marker) (right). 
Note the co-localization of T and B cells within a well-developed ELS surrounding an arteriole 
(a) and next to a vein (v) in the higher magnification images from PBS-treated renal cortex. ELS 
are virtually nonexistent in C4BP(-)-treated renal cortex. Scale bars: 100 m.
Figure 8.- C4BP(-) attenuates autoimmune lupus manifestations in MRL/lpr mice. 
(a) Schematic administration schedule and dosage for intraperitoneal (ip) injection of C4BP(-) 
and vehicle (PBS) (blue arrows), and cyclophosphamide (CYP) (red arrows) in MRL/lpr mice. 
(b) Proteinuria was monitored bimonthly (unless otherwise stated) over the course of the assay 
from week 9 until week 22. Total 24-h urinary protein was determined by Pyrogallol Red-
molybdate protein dye-binding assay. Data are normalized by mouse weight and expressed as 
cumulative mean values (PBS, n= 8; C4BP(-) and CYP, n= 6); *p < 0.05; **p < 0.01 compared 
with control, PBS-treated mice. (c) Kaplan-Meier survival curves from lupus-prone MRL/lpr 
mice. Cumulative survival curves showed 100% survival (8/8) in the CYP-treated and C4BP(-)-
treated mice, and 62.5% survival (5/8) in PBS-treated mice at the end of the study (day 147). Red 
arrows identify the start (day 70) and the end (day 147) of the treatment period. n=6-8 
mice/group; *p < 0.05, compared with vehicle PBS-treated mice; long-rank test. (d) 
Representative sections of renal cortex from 22-week old MRL/lpr mice treated with CYP (left), 
C4BP(-) (center) and vehicle PBS (right) mice stained with hematoxylin and eosin. Images are 
shown at 200 m magnification. The data obtained were used to semi-quantitatively grade 
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histopathology traits indicating active LN (mesangial expansion, endocapillary proliferation, 
glomerular deposits, extracapillary proliferation and interstitial infiltrates), as well as chronic 
lesions (tubular atrophy and interstitial fibrosis) (n= 3 mice/group) (e) Clinical features of 
dermatitis in MRL-lpr mice treated with C4BP(-) (left panels) or PBS (right panels). Major 
lesions were observed around the facial and scapular regions, and vasculitis was evident in the 
ears of PBS-treated mice. Skin lesion severity score at weeks 19 and 21 for each of the study 
groups is shown on the right (PBS, n= 5; C4BP(-) and CYP, n= 6); *p < 0.05; **p < 0.01 
compared with PBS-treated mice. 
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Table 1.- Pathway annotation of NZBW F1 renal genes downregulated by C4BP(-) 





Network connectivity of C4BP(β-)-induced genes 
(Links)
Ms4a1 Prtn3 Tnfrsf13c Lat Cd19 S100a8 S100a9 Irf7
Human 
diseases
14 Systemic lupus 
erythematosus
2.20x10-3






        









        












        










        
Green boxes represent query genes linked to the pathway; Purple boxes indicate genes which are part of the pathway. Darker shades indicate 
higher connectivity. 
FWER: Family-Wise Error Rate.
#: Order number. The results are sorted by increasing FWER.
 
5 1 1
4 1 4 4
3 2 3 1
5 1 1
1 7
3 5 2 1 1
7 2 1
4 2 1
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SUPPLEMENTARY FIGURE CAPTIONS
Supplementary Figure S1.- Human C4BP(-) down-regulates CD80 and CD86 co-
stimulatory molecules in mouse BMDCs stimulated through the TLR7 agonist 
gardiquimod.  Mouse BMDCs, generated as described in Supplementary Methods, were 
incubated throughout their differentiation and maturation process with 5 g/ml of human 
C4BP(-). BMDC maturation was achieved by gardiquimod treatment (10 g/ml). Cells were 
then collected, washed, and analyzed by flow cytometry for cell surface expression of CD80 and 
CD86 surface markers. (a) Histograms from one representative experiment are shown. The MFIs 
for the cell surface markers are indicated in each histogram. (b) MFI for CD80 and CD86 cell 
surface markers. iDC, untreated, immature BMDCs; mDC, untreated, gardiquimod-matured 
BMDCs; C4BP(-), C4BP(-)-treated, gardiquimod-matured BMDCs. The results shown are the 
median +/- IQR from 3 independent experiments (*p < 0.05 compared to mDC).
Supplementary Figure S2.- Time-course of anti-human C4BP(-) antibody development in 
lupus-prone NZBWF1 mice. Serum levels of anti-human C4BP(-) antibody production were 
measured by ELISA from week 20 (pretreatment) to week 36. The anti-human C4BP(-) 
antibody titer increased progressively with the time in the C4BP(-)-treated mice. 
Cyclophosphamide (CYP), used as a negative control group, did not develop anti-human 
C4BP(-)-specific antibodies at any time of the study period. Data are expressed as mean O.D. 
(450 nm) + SD (n= 6 mice/group). ****p < 0.0001 compared with CYP-treated mice.
Supplementary Figure S3.- Renal function determination in lupus-prone NZBW F1 mice 
after subcutaneous administration low-dose rC4BP(-). (a) Schematic administration 
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schedule and dosage for subcutaneous (sc) injection of C4BP(-) and vehicle (PBS) (blue 
arrows), and cyclophosphamide (CYP) (red arrows) in NZBW F1 mice. (b) Unless otherwise 
indicated, proteinuria was monitored monthly over the course of the assay until week 37. Total 
24-h urinary protein was determined by Pyrogallol Red-molybdate protein dye-binding assay. 
Data are normalized by mouse weight and expressed as mean values + SD (n= 6 mice/group); *p 
< 0.05; ***p < 0.001; ****p < 0.0001 compared with control, PBS-treated mice. (c) Time-course 
of anti-human rC4BP(-) antibody development from rC4BP(-)-treated NZBWF1 mice. Serum 
levels of anti-human rC4BP(-) antibody production were measured by ELISA from week 21 
(pretreatment) to week 37. The anti-human rC4BP(-) antibody titer increased progressively 
with the time in the rC4BP(-)-treated mice. Cyclophosphamide (CYP), used as a negative 
control group, did not develop anti-human rC4BP(-)-specific antibodies at any time of the study 
period. Data are expressed as mean O.D. (450 nm) + SD (n= 6 mice/group). ****p < 0.0001 
compared with CYP-treated mice. (d) Kaplan-Meier survival curves from lupus-prone NZBWF1 
mice. Cumulative survival curves showed 100% survival in the CYP-treated mice (6/6), and 67% 
survival (4/6) in C4BP(-)-treated mice at the end of the study (day 337), while all vehicle PBS-
treated mice died by day 313 (0/6). Red arrows identify the start (day 168) and the end (day 252) 
of the treatment period (n=6 mice/group); *p < 0.05; ****p < 0.0001, compared with vehicle 
PBS-treated mice; long-rank test.
Supplementary Figure S4.- Comparative LN pathology determination in lupus-prone 
NZBW F1 mice after administration of both C4BP isoforms: C4BP(+) and C4BP(-). (a) 
Schematic administration schedule and dosage for intraperitoneal (ip) injection of C4BP(+), 
C4BP(-) and vehicle (PBS) (blue arrows) in NZBW F1 mice. (b) Proteinuria was monitored 
monthly over the course of the assay from week 21 until week 35. Total 24-h urinary protein was 
determined by Pyrogallol Red-molybdate protein dye-binding assay. Data are normalized by 
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mouse weight and expressed as cumulative mean values (n= 8 mice/group); *p < 0.05 compared 
with C4BP(+)-treated and control, PBS-treated mice. (c) Blood urea nitrogen (BUN) levels 
were assessed by a coupled enzyme reaction both before (week 21) and during (weeks 29 and 
33) C4BP treatment. Data are expressed as mean + SD (n= 4 mice/group); *p < 0.05; **p < 0.01, 
compared with C4BP(+)-treated mice (w33). (d) Serum levels of anti-dsDNA antibodies 
correlating with disease activity were measured by ELISA 1 week and 5 weeks after the start of 
the treatment (weeks 25 and 29). Data are expressed as mean + SD (n= 3 mice/group); *p < 0.05 
compared with C4BP(+)-treated mice (w25); *p < 0.05 compared with vehicle PBS-treated 
mice (w29). (e) Kaplan-Meier survival curves from lupus-prone NZBW F1 mice. Cumulative 
survival curves showed 100% survival (8/8) in the C4BP(-)-treated mice, 75% survival (6/8) in 
PBS-treated mice, and 62.5% survival (5/8) in PBS-treated mice at the end of the study (day 
252). Red arrows identify the start (day 168) and the end (day 252) of the treatment period (n= 8 
mice/group; *p = 0.06), compared with C4BP(+)-treated mice; long-rank test. (f) 
Representative sections of renal cortex from 36-week old mice treated with C4BP(+) (left), 
C4BP(-) (center) and vehicle PBS (right) mice stained with hematoxylin and eosin. Images are 
shown at 200 m magnification. The data obtained were used to semi-quantitatively grade 
histopathology traits indicating active LN (mesangial expansion, endocapillary proliferation, 
glomerular deposits, extracapillary proliferation and interstitial infiltrates), as well as chronic 
lesions (tubular atrophy and interstitial fibrosis) (n= 3 mice/group). 
Supplementary Figure S5.- Effect of C4BP(+) and C4BP(-) treatment in the activity of 
the classical pathway of complement from NZBW F1 mouse sera. The activity of the 
classical pathway of complement was measured as deposition of C3b on antibody-opsonized 
K562 cells and incubated with mouse sera for 30 min at 37 ºC. Deposited C3b was detected 
using a FITC-labelled antibody and flow cytometry. MFI, median fluorescence intensity. 
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Complement activity levels of NZW F1 mice analyzed before the start of C4BP treatment (week 
21; n= 6 mice/group) and throughout the treatment (weeks 25 (n= 6 mice/group), 29 and 33 (n= 
3 mice/group)). Data are expressed as mean + SD. *p < 0.05 compared with both C4BP(+)-
treated and PBS-treated mice. Serum from C57BL6 mice (14-week old; n= 4) was included as a 
reference control for normal complement activity. Negative controls (Inact.) from all analyzed 
samples were determined after serum inactivation at 56 ºC for 30 min.  
Supplementary Figure S6.- Electrophoretic analysis of plasma-purified human C4BP(+) 
and C4BP(-) isoforms. Both plasma-purified human C4BP(+) and C4BP(-) underwent 3-
8% gradient SDS-PAGE under non-reducing (NR) and reducing (R) conditions. Under NR 
conditions, C4BP(-) is an homooligomer composed of 7 identical -chains, and C4BP(+) is an 
heterooligomer composed of 7 identical -chains and a unique -chain. All chains are covalently 
linked by their C-termini forming a spider-like structure in both isoforms, which migrate as a 
500-570 kDa band (upper arrow). The -chain is always in complex with the vitamin K-
dependent anticoagulant PS (70 kDa).  Thus, under reducing conditions, the diffuse 70 kDa band 
(lower arrow) corresponds to the disassembled -chains in the case of the C4BP(-) isoform, and 
to the disassembled PS plus the -chains in the case of the C4BP(+) isoform. MW marker: 
molecular weight marker.
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C4BP(-) purification from human plasma (40 liters) involved BaCl2 precipitation 
followed by four sequential chromatography steps including heparin chromatography, 
hydrophobic interaction (butyl) chromatography, anion exchange (Q Sepharose) chromatography 
and, finally, size exclusion (Superdex) chromatography. Analogously, Recombinant C4BP(-) 
(rC4BP(-)) was transiently produced in HEK293cells (Expi293 cells) and purified from the cell 
culture supernatants through an hydrophobic interaction (butyl)  chromatography followed by an 
anion exchange (Q Sepharose) chromatography, according to Bioingenium protocols 
(Bioingenium, Barcelona, Spain). All C4BP isoforms (plasma-purified C4BP(+) and C4BP(-), 
and rC4BP(-)) were concentrated, dialyzed and recovered in PBS buffer, pH 7.4. The purity of 
C4BP glycoproteins was higher than 85%, as assessed by Tris-Acetate 3-8% SDS-PAGE 
(NuPAGE precast protein gels; ThermoFisher, Waltham, MA, USA) from 6 g protein/lane, and 
further Coomassie Blue staining (Supplementary Figure S6, and data not shown). All C4BP 
proteins employed in the studies were endotoxin-free, as assessed through the Limulus 
amebocyte lysate test (GenScript, Piscataway, NJ, USA). 
CYP (Genoxal®, Baxter Oncology GmbH, Halle/Westfallen, Germany), was 
resuspended in saline and administered at a dose of 2.5 mg in a final volume of 0.13 ml.
Bone marrow-derived DC (BMDC) generation
Femurs and tibiae of female, 14 weeks-old BALB/c mice (Charles River Laboratories, 
Wilmington, MA, USA) were removed and purified from the surrounding muscle tissue by 
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rubbing with sterile tissues and placed in RPMI-1640 medium (Gibco, ThermoFisher). 
Thereafter intact bones were soaked in 70% ethanol for desinfection. Both ends were cut with 
scissors and the marrow was flushed with RPMI-1640 medium, using a 1-ml insulin syringe with 
a 25G needle, onto a cell strainer (BD Biosciences, Bedford, MA, USA) to obtain a uniform 
single-cell suspension. 1x106 viable bone marrow cells were resuspended in  RPMI 1640 
supplemented with 100 mg/ml streptomycin, 100 IU/ml penicillin, 2 mM L-glutamine (all from 
ThermoFischer) and 10% heat-inactivated FBS (Cultek, Madrid Spain) and plated in 60-mm 
culture plates at 37ºC under 5% CO2. For surface phenotype determination, BMDCs were 
generated supplementing cultures with rmGM-CSF (20ng/ml) (Peprotech, London, UK) at days 
0, 3 and 6 of culture. C4BP (β-) was added at 5 μg/ml at days 0 and 3 of culture. At day 6, non-
adherent cells were re-seeded into 24-well plates with fresh medium at 5x105 cells/ml and were 
further stimulated for 24h with 10 g/ml Gardiquimod (InvivoGen, San Diego, CA, USA).
Mice, study design and follow up
Both NZBW F1 and MRL-lpr mouse strains (Jackson Laboratory, Bar Harbor, ME, 
USA) develop spontaneously an autoimmune disease resembling human SLE. The animals were 
maintained under standard laboratory conditions, at 20-24 ºC and 40-70% relative humidity, with 
12-hour fluorescent light/12-hour dark cycle. They were feed standard diet and tap water ad 
libitium.
The selection of the highest C4BP(-) dose for in vivo administration was based in 
previous studies employing complement-related proteins in murine models of immune-
inflammatory pathologies.S1–S3 We opted for the beginning of C4BP(-) and C4BP(+) 
treatments at 24 weeks because it has been reported that when 23 weeks old, while histologically 
normal, NZBW F1 mice already show faint staining of the glomeruli with anti-IgG and increased 
expression of several inflammatory markers.S4 Analogously, at the beginning of C4BP(-) 
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administration, 10 week old MRL-lpr mice were fully hypocomplementemic (data not shown), 
indicative of high levels of circulating ICs and active disease.S5    
Neither toxicity nor behavioral changes were observed in the mice as a consequence of 
C4BP(-), C4BP(+) or CYP administration. Body weight was determined twice monthly 
(NZBW F1 mice) or weekly (MRL-lpr mice) from the beginning to the end of follow-up. Mice 
were placed in metabolic cages to collect 24 h urine specimens before the onset of treatment and 
monthly (NZBW F1 mice) or biweekly (MRL-lpr mice) thereafter. Blood was obtained from the 
tail vein at monthly intervals and at the sacrifice. Kidneys were dissected and processed for 
histological, biochemical and molecular analyses at the end of the study.
In MRL-lpr mice, macroscopic SLE-like skin lesions from the interscapular region, the 
snout and the ears were scored weekly in a semiquantitative manner using a 0 to 4 scoring 
system: 0, no visible skin changes; 1, minimal hair loss with redness and a few scattered lesions; 
2, redness and hair loss with a small area of involvement (< 0,5 cm2); 3, redness, scabbing, and 
lesion(s) with total area > 0.5, but < 1.0 cm2; and 4, redness, scabbing, and lesion(s) with total 
area > 1.0 cm2. 
All experiments were carried out in accordance with current EU legislation on animal 
experimentation and were approved by ‘‘CEEA: Animal Experimentation Ethics Committee”, 
the Institutional Ethics University of Barcelona Committee for Animal Research, and the 
Generalitat de Catalunya (DARP: 8765).
ELISA for anti-human C4BP(-) detection
To assess the development of antibodies against administered human rC4BP(-) by the 
NZBW F1 mice, we set up an indirect ELISA assay. Briefly, we immobilized C4BP(-) (200 
ng/100 l/well, dissolved in coating buffer: 100 mM Na2CO3 / NaHCO3, pH 9.6) by direct 
adsorption in a 96-well plate overnight at 4 ºC. Next, the plate was blocked with Tris-Tween (50 
Page 91 of 121






























































For Peer Review Only
 Luque et al. (September 2019) KI-12-18-1865
8
mM Tris pH 7.4 + 150 mM NaCl + 0.2% Tween 20) + 1% BSA (100 ml/well) for 1h at room 
temp. The collected mouse sera were diluted to 1:500 in Tris-Tween + 1% BSA and incubated in 
duplicate to the plate (100 l/well) for 1.5 h at room temp. Human C4BP(-)-specific antibodies 
were detected by incubation with an anti-mouse IgG horseradish peroxidase (HRP)-conjugated 
secondary antibody (Agilent Technologies, Santa Clara, CA, USA) (1:10,000 dilution) in Tris-
Tween + 1% BSA for 30 min. at room temp. Washing between steps was performed with Tris-
Tween. Finally, the plate was developed with TMB (3,3’,5,5’-tetramethylbenzidine) HRP 
substrate, stopped with sulfuric acid (1N H2SO4) and the absorbances were read at 450 nm in a 
microtiter plate reader. Negative controls included sera from CYP- and PBS-treated mice.  
Flow cytometry
Cell surface phenotypes were analyzed using FITC-conjugated anti–CD80 (16-10A1) and 
PE-conjugated anti-CD86 (PO3.3) mAbs (all from Miltenyi Biotec, Bergisch Gladbach, 
Germany). After washing with PBS, cells were subsequently stained with 3μl mAbs/105 cells in 
100 l FACS buffer (PBS containing 1% BSA and 0.1% sodium azide) for 15 min at room 
temperature. To exclude debris, BMDCs were gated according to forward scatter (FSC) and side 
scatter (SSC) parameters. Staining with 7-aminoactinomycin D (ThermoFischer) was also 
employed to assess the viability status of BMDCs. Stained cells were analyzed using a 
FACSCanto II flow cytometer equipped with FACSDiva software (Becton Dickinson, Franklin 
Lakes, NJ, USA). Subsequent analyses were performed through FlowJo software (Flowjo LLC, 
Ashland, OR, USA).
Renal histopathology
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To determine the extent of renal damage, all sections were analyzed by two blinded 
pathologists. Typical glomerular active lesions of LN were evaluated: mesangial expansion, 
endocapillary proliferation, glomerular deposits, extracapillary proliferation and interstitial 
infiltrates, as well as tubulointerstitial chronic lesions: tubular atrophy and interstitial fibrosis. 
Lesions were graded semi-quantitatively using a four-point scoring system: (-) null, (+) low, (++) 
moderate, (+++) severe. Glomerular cross-sectional area (µm2) was calculated based on 
average area of 150 glomeruli in each group, from digitized images taken at x100 (3 
mice/group), measured using ImageJ v1.52c software (http://fiji.sc/; NIH, Bethesda, MD, 
USA).
Immunofluorescent determination of renal IC and complement deposition
Kidney slices were fixed in 4% paraformaldehyde, embedded in Tissue Tec OCT 
compound (Sakura, Alpen aan den Rijn, Netherlands) and stored at -80 ºC. Five-m cryostat 
sections were used for confocal microscopy to quantify the mean fluorescence intensity of the 
Cy5.5 fluorochrome. At least 10 glomeruli per section were visualized and photographed with an 
immunofluorescence confocal microscope Leica TCS-SL spectral (Leica Microsystems GmbH, 
Wetzlar, Germany). Fluorescence was quantified with Leica software and expressed as mean 
fluorescence intensity (MFI).
Complement activity assay
The activity of the classical pathway of complement was determined by C3b deposition 
on K562 cells (ATCC, LGC Standards, Barcelona, Spain) opsonized with rabbit polyclonal 
antibodies (Agrisera, Vännäs, Sweden). Briefly, K562 cells were cultured in suspension in 
Dulbecco modified Eagle medium (DMEM) supplemented with 10% heat-inactivated FBS, 100 
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mg/ml streptomycin, 100 IU/ml penicillin, 2 mM L-glutamine (all from ThermoFischer). The 
cells were washed twice in cold PBS, and 106 cells were added to reaction tubes containing PBS 
with 2 mM MgCl2, 0.15 mM CaCl2, 5 mg/ml of opsonizing antibodies and 10% mouse sera in a 
total volume of 100 μl. After 30 min incubation at 37ºC, cells were washed with cold FACS 
buffer. The amount of deposited C3b was measured using FITC-conjugated goat IgG fraction to 
mouse complement C3 antibody (MP Biomedicals, Solon, OH, USA) diluted 1:100, and allowed 
to bind for 1 h at 4ºC. The cells were washed three times, resuspended with cold FACS buffer, 
and analyzed in a FACSCanto II flow cytometer equipped with FACSDiva software (Becton 
Dickinson).
Immunohistochemistry
Paraffin-processed sections (5 µm) were deparaffinized in xylene, rehydrated in graded 
ethanol solutions, rinsed in distilled water and treated with 3% hydrogen peroxide in methanol 
(30 min at room temp. (RT)) to remove endogenous peroxidase activity. The sections were 
further incubated 30 min at RT with blocking solution (5% goat serum, 0.1% Tween 20 in PBS, 
pH 7.2), and incubated overnight at 4ºC with the primary antibodies, washed in PBS and 
incubated with the appropriate secondary antibodies for 30-60 min at RT. Colour was developed 
using 3,3’-diaminobenzidine (DAB) and sections were counterstained with hematoxylin before 
dehydration, clearing, and mounting. Negative controls in which the primary antibody was 
replaced with PBS were used to test for non-specific binding (data not shown).
TUNEL Assay
Briefly, 5 μm thick deparaffinized sections were pretreated with proteinase K for 30 min 
at RT. After washing in deionized water, the endogenous peroxidase was inactivated using 3% 
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H2O2 in methanol for 5 min, followed by incubation with TdT enzyme at 37°C for 1 h. Next, 
sections were immersed in TdT Stop buffer and incubated with Streptavidin-HRP solution at 37 
ºC for 10 min followed by DAB solution. Slices were counterstained with 1% methyl green. 
TUNEL-positive cells were assessed by light microscopy. The number of cortical apoptotic cells 
was quantified in 10 fields from 3 section samples/group and given as apoptotic cells/field. Ten 
glomeruli per section (30 glomeruli/group) were also quantified to establish the number of 
apoptotic cells per glomerular cut section (cells/gcs). ImageJ v1.52c software (NIH) was 
employed to analyze digitized images at x200 and x400, respectively.
Differential gene expression analysis
Total RNA from mouse kidneys was extracted using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany). Reverse transcription was performed using the High-capacity cDNA archive 
kit (Applied BioSystems, Carlsbad, CA, USA). Gene expression profiling was performed in 384-
well microfluidic cards pre-loaded with 377 gene expression assays for transcripts relevant in 
murine LN. S6-S8 Four wells per card included the 18S gene expression assay as internal control. 
We used one card for each pool (2-3 mice/pool; 3 cards/group). Data were obtained with SDS 
v2.4 and RQ Manager v1.2.1, analyzed with DataAssist software v3.0 (all from Applied 
Biosystems) and normalized using 3 endogenous controls (Actb, Gapdh and Gusb). The values 
obtained were relativized using the vehicle PBS-treated group as reference.
Differentially expressed genes were analyzed using the Ingenuity Pathway Analysis 
(IPA) (Ingenuity Systems, Qiagen) to identify biological and molecular networks differentially 
regulated in the LN model. IPA core analysis is a source of gene-interaction based pathway 
analysis including canonical pathways and a knowledge database based on scientific findings. 
Differentially expressed genes at least 1.8-fold upregulated or downregulated were imported and 
analyzed in the IPA database. Based on the direct or indirect connectivity of genes as disclosed 
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in the literature, genes were mapped onto biological pathways and disease networks. A P value 
of < 0.05 (Fisher exact test) was used as the cutoff for significant biological functions, networks, 
and pathways, and they were ranked by ratio. Downstream effects analysis was undertaken to 
identify key biological processes influenced by differentially expressed genes. Statistical 
significance of the overlap between two groups of genes from our dataset and from the 
“Ingenuity® Knowledge Base” was given as overlap p-value, and significant process or pathway 
directionality was predicted when 2 < Z-score < -2. 
Selected gene transcripts were further validated in individual mouse kidney samples by 
RT-qPCR using the corresponding inventoried TaqMan Gene Expression Assays (Applied 
BioSystems). Quantification was achieved through the ΔΔCt method. A relative fold change in 
mRNA abundance was calculated with the equation 2-ΔΔCt, employing Gusb as endogenous 
reference transcript. 
Pathway annotation of the RT-qPCR-validated gene set was performed through 
PathwAX, which uses the comprehensive network FunCoup to analyze network crosstalk 
between a query gene list and KEGG pathways. 
Mouse cytokine array
Serum was obtained by centrifugation of blood samples at sacrifice (1500 g, 10 min, 
4ºC). Tissue lysates were obtained by kidney homogenization in PBS supplemented with the 
protease inhibitors aprotinin (Sigma-Aldrich), leupeptin and pepstatin (both from Tocris 
Bioscience, Bristol, UK) (all 10μg/ml) using a Dounce Homogenizer (Knotes Glass, Vineland, 
NJ, USA). Triton X-100 was added to a final concentration of 1% before the lysates underwent 
freezing at -80°C. After thawing, the lysates were centrifuged at 10000 g for 5 min. Pooled 
samples (100 l serum, or 300 g protein extracts; 2 mice/group) were analyzed using the 
Proteome Profiler Array “Mouse Cytokine Array Panel A” kit (R&D Systems), according to the 
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manufacturer’s instructions, to determine the relative levels of 40 cytokines and chemokines and 
acute phase proteins.
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 Table S1.- List of relevant SLE genes included in the customized TaqMan Low Density Array.
Gene 
Symbol
Assay ID UniGene 
ID
Gene name
Acad8 Mm00482266_m1 Mm.289244 acyl-Coenzyme A dehydrogenase family, member 8
Ace Mm00802048_m1 Mm.754 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
Acsl1 Mm00484217_m1 Mm.210323 acyl-CoA synthetase long-chain family member 1
Acsl3 Mm01255804_m1 Mm.276016 acyl-CoA synthetase long-chain family member 3
Actr3 Mm02342769_g1 Mm.183102 ARP3 actin-related protein 3
Ada Mm00545720_m1 Mm.388 adenosine deaminase
Adh1 Mm00507711_m1 Mm.2409 alcohol dehydrogenase 1 (class I)
Adh7 Mm00507750_m1 Mm.8473 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide
Adhfe1 Mm00613830_m1 Mm.28514 alcohol dehydrogenase, iron containing, 1
Adsl Mm00507759_m1 Mm.38151 adenylosuccinate lyase
Agt Mm00599662_m1 Mm.301626 angiotensinogen (serpin peptidase inhibitor, clade A, member 8)
Ahcyl1 Mm00461101_m1 Mm.220328 S-adenosylhomocysteine hydrolase-like 1
Ahcyl2 Mm00619649_m1 Mm.210899 S-adenosylhomocysteine hydrolase-like 2
Aifm1 Mm00442540_m1 Mm.240434 apoptosis-inducing factor, mitochondrion-associated 1
Aim2 Mm01295719_m1 Mm.131453 absent in melanoma 2
Akr1a1 Mm00480608_m1 Mm.30085 aldo-keto reductase family 1, member A1 (aldehyde reductase)
Aldh2 Mm00477463_m1 Mm.284446 aldehyde dehydrogenase 2, mitochondrial
Aldh3a2 Mm00839320_m1 Mm.398221 aldehyde dehydrogenase family 3, subfamily A2
Aldh3b1 Mm00550698_m1 Mm.109341 aldehyde dehydrogenase 3 family, member B1
Aldh4a1 Mm00615268_m1 Mm.273571 aldehyde dehydrogenase 4 family, member A1
Aldh6a1 Mm00506227_m1 Mm.247510 aldehyde dehydrogenase family 6, subfamily A1
Aldh7a1 Mm00519645_m1 Mm.30250 aldehyde dehydrogenase family 7, member A1
Aldh9a1 Mm00480240_m1 Mm.292539 aldehyde dehydrogenase 9, subfamily A1
Apoc3 Mm00445670_m1 Mm.390161 apolipoprotein C-III
Apoe Mm01307193_g1 Mm.305152 apolipoprotein E
Arf6 Mm00500208_s1 Mm.27308 ADP-ribosylation factor 6
Arg1 Mm00475988_m1 Mm.154144 arginase, liver
Arg2 Mm00477592_m1 Mm.3506 arginase type II
Arpc1b Mm00834862_m1 Mm.30010 actin related protein 2/3 complex, subunit 1B
Arpc2 Mm01254383_m1 Mm.337038 actin related protein 2/3 complex, subunit 2
Arpc3 Mm01199871_m1 Mm.275942 actin related protein 2/3 complex, subunit 3
Arpc5 Mm04208715_m1 Mm.288974 actin related protein 2/3 complex, subunit 5
Atf4 Mm00515325_g1 Mm.641 activating transcription factor 4
Atp5b Mm00443967_g1 Mm.238973 ATP synthase, H+ transporting mitochondrial F1 complex, beta 
subunit
Atp5f1 Mm01296543_g1 Mm.251152 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
B1
Atp5g3 Mm01334541_g1 Mm.2966 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
C3 (subunit 9)
Auh Mm00479363_m1 Mm.252034 AU RNA binding protein/enoyl-coenzyme A hydratase
B2m Mm00437762_m1 Mm.163 beta-2 microglobulin
Batf3 Mm01318274_m1 Mm.6922 basic leucine zipper transcription factor, ATF-like 3
Bckdha Mm00476112_m1 Mm.25848 branched chain ketoacid dehydrogenase E1, alpha polypeptide
Bckdhb Mm01177077_m1 Mm.12819 branched chain ketoacid dehydrogenase E1, beta polypeptide
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Blk Mm00432077_m1 Mm.3962 B lymphoid kinase
Btk Mm00442712_m1 Mm.4475 Bruton agammaglobulinemia tyrosine kinase
C1qa Mm00432142_m1 Mm.439957 complement component 1, q subcomponent, alpha polypeptide
C1qb Mm01179619_m1 Mm.2570 complement component 1, q subcomponent, beta polypeptide
C1qc Mm00776126_m1 Mm.439732 complement component 1, q subcomponent, C chain
C1ra Mm04206253_g1 Mm.333375 complement component 1, r subcomponent A
C1s1 Mm00663210_mH Mm.219527 complement component 1, s subcomponent 1
C3 Mm00437838_m1 Mm.19131 complement component 3
C3ar1 Mm02620006_s1 Mm.2408 complement component 3a receptor 1
C4bp Mm00432150_m1 Mm.306720 complement component 4 binding protein
C6 Mm00489521_m1 Mm.20247 complement component 6
C8a Mm00521627_m1 Mm.197638 complement component 8, alpha polypeptide
C9 Mm00442739_m1 Mm.29095 complement component 9
Casp1 Mm00438023_m1 Mm.1051 caspase 1
Casp3 Mm01195085_m1 Mm.34405 caspase 3
Cat Mm00437992_m1 Mm.4215 catalase
Cbs Mm00460654_m1 Mm.206417 cystathionine beta-synthase
Ccl2 Mm00441242_m1 Mm.290320 chemokine (C-C motif) ligand 2
Ccl5 Mm01302427_m1 Mm.284248 chemokine (C-C motif) ligand 5
Ccl9 Mm00441260_m1 Mm.416125 chemokine (C-C motif) ligand 9
Ccr1 Mm00438260_s1 Mm.274927 chemokine (C-C motif) receptor 1
Ccr2 Mm00438270_m1 Mm.6272 chemokine (C-C motif) receptor 2
Ccr5 Mm01963251_s1 Mm.14302 chemokine (C-C motif) receptor 5
Ccr6 Mm99999114_s1 Mm.8007 chemokine (C-C motif) receptor 6
Ccr7 Mm01301785_m1 Mm.2932 chemokine (C-C motif) receptor 7
Ccs Mm00444148_m1 Mm.434411 copper chaperone for superoxide dismutase
Cd14 Mm00438094_g1 Mm.3460 CD14 antigen
Cd19 Mm00515420_m1 Mm.4360 CD19 antigen
Cd1d1 Mm00783541_s1 Mm.1894 CD1d1 antigen
Cd207 Mm00523545_m1 Mm.136079 CD207 antigen
Cd22 Mm00515432_m1 Mm.260994 CD22 antigen
Cd274 Mm00452054_m1 Mm.245363 CD274 antigen
Cd276 Mm00506020_m1 Mm.5356 CD276 antigen
Cd28 Mm00483137_m1 Mm.255003 CD28 antigen
Cd300lb Mm01701741_m1 Mm.185355 CD300 antigen like family member B
Cd3d Mm00442746_m1 Mm.4527 CD3 antigen, delta polypeptide
Cd3g Mm00438095_m1 Mm.335106 CD3 antigen, gamma polypeptide
Cd40 Mm00441891_m1 Mm.271833 CD40 antigen
Cd40lg Mm00441911_m1 Mm.4861 CD40 ligand
Cd48 Mm00455932_m1 Mm.1738 CD48 antigen
Cd5 Mm00432417_m1 Mm.779 CD5 antigen
Cd74 Mm00658576_m1 Mm.439737 CD74 antigen (invariant polypeptide of major histocompatibility 
complex, class II antigen-associated)
Cd79b Mm00434143_m1 Mm.2987 CD79B antigen
Cd80 Mm00711660_m1 Mm.89474 CD80 antigen
Cd83 Mm00486868_m1 Mm.57175 CD83 antigen
Cd86 Mm00444543_m1 Mm.1452 CD86 antigen
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Cdt1 Mm00466006_m1 Mm.21873 chromatin licensing and DNA replication factor 1
Cebpb Mm00843434_s1 Mm.439656 CCAAT/enhancer binding protein (C/EBP), beta
Cfb Mm00433918_g1 Mm.653 complement factor B
Cfh Mm01299248_m1 Mm.8655 complement component factor h
Cfi Mm00432470_m1 Mm.117180 complement component factor i
Chek2 Mm00443839_m1 Mm.279308 checkpoint kinase 2
Chga Mm00514341_m1 Mm.4137 chromogranin A
Cldn1 Mm00516701_m1 Mm.289441 claudin 1
Cldn7 Mm00516817_m1 Mm.281896 claudin 7
Clec10a Mm00546125_g1 Mm.252405 C-type lectin domain family 10, member A
Clec4n Mm00490934_m1 Mm.271782 C-type lectin domain family 4, member n
Clec7a Mm01183349_m1 Mm.239516 C-type lectin domain family 7, member a
Clu Mm01197002_m1 Mm.200608 clusterin
Col18a1 Mm00487131_m1 Mm.4352 collagen, type XVIII, alpha 1
Col1a1 Mm00801666_g1 Mm.277735 collagen, type I, alpha 1
Col1a2 Mm00483888_m1 Mm.277792 collagen, type I, alpha 2
Col3a1 Mm01254476_m1 Mm.249555 collagen, type III, alpha 1
Col4a1 Mm01210125_m1 Mm.738 collagen, type IV, alpha 1
Cox11 Mm01615963_g1 Mm.151940 cytochrome c oxidase assembly protein 11
Cox15 Mm00523096_m1 Mm.248237 cytochrome c oxidase assembly protein 15
Cox5a Mm01176957_g1 Mm.273403 cytochrome c oxidase subunit Va
Cox5b Mm00833840_g1 Mm.180182 cytochrome c oxidase subunit Vb
Cox6a1 Mm01612194_m1 Mm.43415 cytochrome c oxidase subunit VIa polypeptide 1
Cox6b1 Mm00824357_m1 Mm.400 cytochrome c oxidase, subunit VIb polypeptide 1
Cox8a Mm02342396_g1 Mm.14022 cytochrome c oxidase subunit VIIIa
Cpeb1 Mm01314928_m1 Mm.273122 cytoplasmic polyadenylation element binding protein 1
Csf1 Mm00432686_m1 Mm.795 colony stimulating factor 1 (macrophage)
Csf1r Mm01266652_m1 Mm.22574 colony stimulating factor 1 receptor
Csf2rb Mm00655745_m1 Mm.235324 colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-
macrophage)
Cst7 Mm00438349_m1 Mm.12965 cystatin F (leukocystatin)
Ctgf Mm01192932_g1 Mm.390287 connective tissue growth factor
Ctla4 Mm00486849_m1 Mm.390 cytotoxic T-lymphocyte-associated protein 4
Ctss Mm01255859_m1 Mm.3619 cathepsin S
Cx3cl1 Mm00436454_m1 Mm.103711 chemokine (C-X3-C motif) ligand 1
Cx3cr1 Mm02620111_s1 Mm.44065 chemokine (C-X3-C motif) receptor 1
Cxcl1 Mm04207460_m1 Mm.21013 chemokine (C-X-C motif) ligand 1
Cxcl10 Mm00445235_m1 Mm.877 chemokine (C-X-C motif) ligand 10
Cxcl11 Mm00444662_m1 Mm.131723 chemokine (C-X-C motif) ligand 11
Cxcl13 Mm04214185_s1 Mm.10116 chemokine (C-X-C motif) ligand 13
Cxcl16 Mm00469712_m1 Mm.425692 chemokine (C-X-C motif) ligand 16
Cxcl2 Mm00436450_m1 Mm.4979 chemokine (C-X-C motif) ligand 2
Cxcl9 Mm00434946_m1 Mm.766 chemokine (C-X-C motif) ligand 9
Cxcr4 Mm01996749_s1 Mm.1401 chemokine (C-X-C motif) receptor 4
Cxcr6 Mm02620517_s1 Mm.124289 chemokine (C-X-C motif) receptor 6
Cyc1 Mm00470540_m1 Mm.29196 cytochrome c-1
Dbf4 Mm01324087_m1 Mm.292470 DBF4 homolog (S. cerevisiae)
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Ddr1 Mm01273496_m1 Mm.5021 discoidin domain receptor family, member 1
Dhrs4 Mm00472717_m1 Mm.27427 dehydrogenase/reductase (SDR family) member 4
Dld Mm00432831_m1 Mm.3131 dihydrolipoamide dehydrogenase
Dnaja1 Mm00787254_s1 Mm.27897 DnaJ (Hsp40) homolog, subfamily A, member 1
Egln3 Mm00472200_m1 Mm.133037 egl-9 family hypoxia-inducible factor 3
Eng Mm00468256_m1 Mm.225297 endoglin
Ep300 Mm00625535_m1 Mm.258397 E1A binding protein p300
Epas1 Mm01236112_m1 Mm.1415 endothelial PAS domain protein 1
Ephx2 Mm01313813_m1 Mm.15295 epoxide hydrolase 2, cytoplasmic
Ereg Mm00514794_m1 Mm.4791 epiregulin
F3 Mm00438853_m1 Mm.273188 coagulation factor III
Fasl Mm00438864_m1 Mm.3355 Fas ligand (TNF superfamily, member 6)
Fcer1g Mm02343757_m1 Mm.22673 Fc receptor, IgE, high affinity I, gamma polypeptide
Fcgr1 Mm00438874_m1 Mm.150 Fc receptor, IgG, high affinity I
Fcgr3 Mm00438882_m1 Mm.22119 Fc receptor, IgG, low affinity III
Fcgr4 Mm00519988_m1 Mm.251254 Fc receptor, IgG, low affinity IV
Fga Mm00802584_m1 Mm.88793 fibrinogen alpha chain
Fgb Mm00805336_m1 Mm.30063 fibrinogen beta chain
Fgg Mm00513575_m1 Mm.16422 fibrinogen gamma chain
Fli1 Mm00484410_m1 Mm.258908 Friend leukemia integration 1
Fmo1 Mm00515795_m1 Mm.976 flavin containing monooxygenase 1
Fmo2 Mm00490159_m1 Mm.10929 flavin containing monooxygenase 2
Fmo4 Mm00467393_m1 Mm.155164 flavin containing monooxygenase 4
Fn1 Mm01256744_m1 Mm.193099 fibronectin 1
Fos Mm00487425_m1 Mm.246513 FBJ osteosarcoma oncogene
Foxp3 Mm00475162_m1 Mm.182291 forkhead box P3
Fyn Mm00433373_m1 Mm.4848 Fyn proto-oncogene
Got1 Mm01195792_g1 Mm.19039 glutamic-oxaloacetic transaminase 1, soluble
Gpnmb Mm01328587_m1 Mm.302602 glycoprotein (transmembrane) nmb
Gss Mm00515065_m1 Mm.252316 glutathione synthetase
Gsto1 Mm00599866_m1 Mm.378931 glutathione S-transferase omega 1
Havcr1 Mm00506686_m1 Mm.17771 hepatitis A virus cellular receptor 1
Hck Mm01241463_m1 Mm.715 hemopoietic cell kinase
Hmox1 Mm00516005_m1 Mm.276389 heme oxygenase 1
Hnf4a Mm01247712_m1 Mm.202383 hepatic nuclear factor 4, alpha
Hspe1 Mm00434083_m1 Mm.215667 heat shock protein 1 (chaperonin 10)
Icam1 Mm00516023_m1 Mm.435508 intercellular adhesion molecule 1
Icos Mm00497600_m1 Mm.42044 inducible T cell co-stimulator
Id1 Mm00775963_g1 Mm.444 inhibitor of DNA binding 1
Idh1 Mm00516030_m1 Mm.9925 isocitrate dehydrogenase 1 (NADP+), soluble
Idh3a Mm00499674_m1 Mm.279195 isocitrate dehydrogenase 3 (NAD+) alpha
Idh3b Mm00504589_m1 Mm.29590 isocitrate dehydrogenase 3 (NAD+) beta
Idh3g Mm00599686_g1 Mm.14825 isocitrate dehydrogenase 3 (NAD+), gamma
Ifi202b Mm00839397_m1 Mm.218770 interferon activated gene 202B
Ifi44 Mm00505670_m1 Mm.30756 interferon-induced protein 44
Ifih1 Mm00459183_m1 Mm.136224 interferon induced with helicase C domain 1
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Ifng Mm01168134_m1 Mm.240327 interferon gamma
Igfbp1 Mm00515154_m1 Mm.21300 insulin-like growth factor binding protein 1
Igfbp6 Mm00599696_m1 Mm.358609 insulin-like growth factor binding protein 6
Ikbke Mm00444862_m1 Mm.386783 inhibitor of kappaB kinase epsilon
Ikzf1 Mm01187882_m1 Mm.103545 IKAROS family zinc finger 1
Il10 Mm00439614_m1 Mm.874 interleukin 10
Il10ra Mm00434151_m1 Mm.379327 interleukin 10 receptor, alpha
Il12a Mm00434165_m1 Mm.103783 interleukin 12a
Il12b Mm00434174_m1 Mm.239707 interleukin 12b
Il17a Mm00439618_m1 Mm.5419 interleukin 17A
Il18 Mm00434225_m1 Mm.1410 interleukin 18
Il1b Mm00434228_m1 Mm.222830 interleukin 1 beta
Il1f6 Mm00457645_m1 Mm.133095 interleukin 1 family, member 6
Il1r2 Mm00439629_m1 Mm.1349 interleukin 1 receptor, type II
Il23a Mm01160011_g1 Mm.125482 interleukin 23, alpha subunit p19
Il27 Mm00461162_m1 Mm.222632 interleukin 27
Il27ra Mm00497259_m1 Mm.38386 interleukin 27 receptor, alpha
Il2rg Mm00442885_m1 Mm.2923 interleukin 2 receptor, gamma chain
Il33 Mm00505403_m1 Mm.182359 interleukin 33
Il4 Mm00445259_m1 Mm.276360 interleukin 4
Il7r Mm00434295_m1 Mm.389 interleukin 7 receptor
Inpp5d Mm00494987_m1 Mm.15105 inositol polyphosphate-5-phosphatase D
Irak1 Mm01193538_m1 Mm.38241 interleukin-1 receptor-associated kinase 1
Irf1 Mm01288580_m1 Mm.105218 interferon regulatory factor 1
Irf4 Mm00516431_m1 Mm.4677 interferon regulatory factor 4
Irf5 Mm00496477_m1 Mm.6479 interferon regulatory factor 5
Irf7 Mm00516793_g1 Mm.3233 interferon regulatory factor 7
Irf8 Mm00492567_m1 Mm.334861 interferon regulatory factor 8
Irf9 Mm00492679_m1 Mm.2032 interferon regulatory factor 9
Itga4 Mm01277951_m1 Mm.31903 integrin alpha 4
Itgam Mm00434455_m1 Mm.262106 integrin alpha M
Itgb2 Mm00434513_m1 Mm.1137 integrin beta 2
Jak3 Mm00439973_m1 Mm.249645 Janus kinase 3
Jun Mm00495062_s1 Mm.275071 jun proto-oncogene
Klk11 Mm00480210_g1 Mm.154276 kallikrein related-peptidase 11
Klkb1 Mm00434658_m1 Mm.482691 kallikrein B, plasma 1
Lat Mm00456761_m1 Mm.10280 linker for activation of T cells
Lck Mm00802897_m1 Mm.293753 lymphocyte protein tyrosine kinase
Lcp2 Mm01187570_m1 Mm.265350 lymphocyte cytosolic protein 2
Lrrk2 Mm00481934_m1 Mm.37558 leucine-rich repeat kinase 2
Ltb Mm00434774_g1 Mm.1715 lymphotoxin B
Ly96 Mm01227593_m1 Mm.116844 lymphocyte antigen 96
Lyn Mm01217488_m1 Mm.317331 Yamaguchi sarcoma viral (v-yes-1) oncogene homolog
Maob Mm00555412_m1 Mm.241656 monoamine oxidase B
Map3k1 Mm00803707_m1 Mm.15918 mitogen-activated protein kinase kinase kinase 1
Map3k3 Mm00803725_m1 Mm.27041 mitogen-activated protein kinase kinase kinase 3
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Map3k8 Mm00432637_m1 Mm.3275 mitogen-activated protein kinase kinase kinase 8
Mapk9 Mm00444239_m1 Mm.68933 mitogen-activated protein kinase 9
Mat2b Mm00506137_m1 Mm.293771 methionine adenosyltransferase II, beta
Mmp2 Mm00439498_m1 Mm.29564 matrix metallopeptidase 2
Mmp9 Mm00442991_m1 Mm.4406 matrix metallopeptidase 9
Mpo Mm01298424_m1 Mm.4668 myeloperoxidase
Ms4a1 Mm00545909_m1 Mm.4046 membrane-spanning 4-domains, subfamily A, member 1
Msr1 Mm00446214_m1 Mm.239291 macrophage scavenger receptor 1
Myl9 Mm01251442_m1 Mm.271770 myosin, light polypeptide 9, regulatory
Ncf1 Mm00447921_m1 Mm.425296 neutrophil cytosolic factor 1
Ndrg2 Mm00443481_g1 Mm.26722 N-myc downstream regulated gene 2
Ndufa10 Mm00600325_m1 Mm.248778 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10
Ndufa3 Mm01329704_g1 Mm.17851 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3
Ndufa8 Mm00503351_m1 Mm.19834 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8
Ndufa9 Mm00481216_m1 Mm.29939 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9
Ndufaf1 Mm00452828_m1 Mm.5390 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 1
Ndufb10 Mm01300078_m1 Mm.1129 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10
Ndufb2 Mm01157852_m1 Mm.29415 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2
Ndufb5 Mm00452592_m1 Mm.28058 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5
Ndufb6 Mm01208591_g1 Mm.1103 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6
Ndufs1 Mm00523640_m1 Mm.290791 NADH dehydrogenase (ubiquinone) Fe-S protein 1
Ndufs5 Mm02600127_g1 Mm.42805 NADH dehydrogenase (ubiquinone) Fe-S protein 5
Ndufs7 Mm01144210_m1 Mm.28712 NADH dehydrogenase (ubiquinone) Fe-S protein 7
Nfatc3 Mm01249200_m1 Mm.383185 nuclear factor of activated T cells, cytoplasmic, calcineurin 
dependent 3
Nfkb2 Mm00479810_g1 Mm.102365 nuclear factor of kappa light polypeptide gene enhancer in B cells 
2, p49/p100
Nfkbie Mm01269649_m1 Mm.57043 nuclear factor of kappa light polypeptide gene enhancer in B cells 
inhibitor, epsilon
Nisch Mm00452152_m1 Mm.298728 nischarin
Nlrp3 Mm00840904_m1 Mm.54174 NLR family, pyrin domain containing 3
Nox4 Mm00479246_m1 Mm.31748 NADPH oxidase 4
Npy Mm03048253_m1 Mm.154796 neuropeptide Y
Osmr Mm01307326_m1 Mm.10760 oncostatin M receptor
Park7 Mm00498538_m1 Mm.277349 Parkinson disease (autosomal recessive, early onset) 7
Pcca Mm00454899_m1 Mm.23876 propionyl-Coenzyme A carboxylase, alpha polypeptide
Pccb Mm00452663_m1 Mm.335385 propionyl Coenzyme A carboxylase, beta polypeptide
Pdcd1lg2 Mm00451734_m1 Mm.116737 programmed cell death 1 ligand 2
Pdgfrb Mm00435546_m1 Mm.4146 platelet derived growth factor receptor, beta polypeptide
Pdha1 Mm00468675_m1 Mm.34775 pyruvate dehydrogenase E1 alpha 1
Pik3c2g Mm00440781_m1 Mm.333471 phosphatidylinositol 3-kinase, C2 domain containing, gamma 
polypeptide
Pik3cg Mm00445038_m1 Mm.101369 phosphoinositide-3-kinase, catalytic, gamma polypeptide
Pik3r5 Mm00805206_m1 Mm.244960 phosphoinositide-3-kinase, regulatory subunit 5, p101
Pipox Mm00477190_m1 Mm.8543 pipecolic acid oxidase
Pla2g4a Mm00447040_m1 Mm.4186 phospholipase A2, group IVA (cytosolic, calcium-dependent)
Pla2g7 Mm00479105_m1 Mm.9277 phospholipase A2, group VII (platelet-activating factor 
acetylhydrolase, plasma)
Pla2r1 Mm00476896_m1 Mm.5092 phospholipase A2 receptor 1
Plau Mm01274460_g1 Mm.4183 plasminogen activator, urokinase
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Plcd4 Mm00455768_m1 Mm.290731 phospholipase C, delta 4
Plce1 Mm00457691_m1 Mm.34031 phospholipase C, epsilon 1
Pld4 Mm00626861_m1 Mm.203915 phospholipase D family, member 4
Plekha2 Mm00504233_m1 Mm.261122 pleckstrin homology domain-containing, family A (phosphoinositide 
binding specific) member 2
Pnmt Mm00476993_m1 Mm.57030 phenylethanolamine-N-methyltransferase
Por Mm00435876_m1 Mm.3863 P450 (cytochrome) oxidoreductase
Ppara Mm00440939_m1 Mm.212789 peroxisome proliferator activated receptor alpha
Ppm1l Mm00618786_m1 Mm.40577 protein phosphatase 1 (formerly 2C)-like
Prdx3 Mm00545848_m1 Mm.29821 peroxiredoxin 3
Prdx5 Mm00465365_m1 Mm.279782 peroxiredoxin 5
Prkcb Mm00435749_m1 Mm.207496 protein kinase C, beta
Prkcz Mm00776345_g1 Mm.28561 protein kinase C, zeta
Pros1 Mm01343426_m1 Mm.127156 protein S (alpha)
Prtn3 Mm00478323_m1 Mm.2364 proteinase 3
Psmb8 Mm01278979_m1 Mm.180191 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7)
Psmb9 Mm00479004_m1 Mm.390983 proteasome (prosome, macropain) subunit, beta type 9 (large 
multifunctional peptidase 2)
Ptgs2 Mm00478374_m1 Mm.292547 prostaglandin-endoperoxide synthase 2
Ptpn22 Mm00501246_m1 Mm.395 protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
Ptpn6 Mm00469153_m1 Mm.271799 protein tyrosine phosphatase, non-receptor type 6
Ptprc Mm01293577_m1 Mm.391573 protein tyrosine phosphatase, receptor type, C
Ptx3 Mm00477268_m1 Mm.276776 pentraxin related gene
Pycard Mm00445747_g1 Mm.24163 PYD and CARD domain containing
Rac2 Mm00485472_m1 Mm.1972 RAS-related C3 botulinum substrate 2
Rad23a Mm00436249_g1 Mm.255539 RAD23a homolog (S. cerevisiae)
Rdh14 Mm00502743_m1 Mm.119343 retinol dehydrogenase 14 (all-trans and 9-cis)
Rela Mm00501346_m1 Mm.249966 v-rel reticuloendotheliosis viral oncogene homolog A (avian)
Relb Mm00485664_m1 Mm.1741 avian reticuloendotheliosis viral (v-rel) oncogene related B
Rnase1 Mm00726747_s1 Mm.235538 ribonuclease, RNase A family, 1 (pancreatic)
Robo1 Mm00803879_m1 Mm.310772 roundabout homolog 1 (Drosophila)
S100a8 Mm00496696_g1 Mm.21567 S100 calcium binding protein A8 (calgranulin A)
Saa1 Mm00656927_g1 Mm.148800 serum amyloid A 1
Sardh Mm00454657_m1 Mm.278467 sarcosine dehydrogenase
Scd1 Mm00772290_m1 Mm.267377 stearoyl-Coenzyme A desaturase 1
Sdha Mm01352366_m1 Mm.158231 succinate dehydrogenase complex, subunit A, flavoprotein (Fp)
Serpina1a Mm02748447_g1 Mm.439692 serine (or cysteine) peptidase inhibitor, clade A, member 1A
Serpina1c;
Serpina1a
Mm04207709_gH Mm.439692 serine (or cysteine) peptidase inhibitor, clade A, member 1C
Serpina1d Mm00842094_mH Mm.439695 serine (or cysteine) peptidase inhibitor, clade A, member 1D
Serpina1d;
Serpina1b
Mm04207706_gH Mm.439692 serine (or cysteine) preptidase inhibitor, clade A, member 1B
Serpina1e Mm00833655_m1 Mm.312593 serine (or cysteine) peptidase inhibitor, clade A, member 1E
Serpina6 Mm00432327_m1 Mm.290079 serine (or cysteine) peptidase inhibitor, clade A, member 6
Serpine1 Mm00435860_m1 Mm.250422 serine (or cysteine) peptidase inhibitor, clade E, member 1
Serping1 Mm00437834_m1 Mm.38888 serine (or cysteine) peptidase inhibitor, clade G, member 1
Sh3bp2 Mm00449397_m1 Mm.5012 SH3-domain binding protein 2
Sigirr Mm01275624_g1 Mm.38017 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain
Slc2a4 Mm01245502_m1 Mm.10661 solute carrier family 2 (facilitated glucose transporter), member 4
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Socs3 Mm00545913_s1 Mm.3468 suppressor of cytokine signaling 3
Sod2 Mm01313000_m1 Mm.290876 superoxide dismutase 2, mitochondrial
Sod3 Mm01213380_s1 Mm.2407 superoxide dismutase 3, extracellular
Sord Mm00455377_g1 Mm.371580 sorbitol dehydrogenase
Spi1 Mm00488142_m1 Mm.1302 spleen focus forming virus (SFFV) proviral integration oncogene
Spn Mm01164549_m1 Mm.283714 sialophorin
Spp1 Mm00436767_m1 Mm.288474 secreted phosphoprotein 1
Srr Mm01246014_m1 Mm.131443 serine racemase
Stat1 Mm00439531_m1 Mm.277406 signal transducer and activator of transcription 1
Stat3 Mm01219775_m1 Mm.249934 signal transducer and activator of transcription 3
Stat4 Mm00448890_m1 Mm.1550 signal transducer and activator of transcription 4
Suox Mm00620388_g1 Mm.23352 sulfite oxidase
Surf1 Mm00489041_g1 Mm.347512 surfeit gene 1
Syk Mm01333032_m1 Mm.375031 spleen tyrosine kinase
Tap1 Mm00443188_m1 Mm.482076 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Tap2 Mm01277033_m1 Mm.14814 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)
Tapbp Mm00493417_m1 Mm.154457 TAP binding protein
Tgfb1 Mm01178820_m1 Mm.248380 transforming growth factor, beta 1
Tgfbr1 Mm00436964_m1 Mm.197552 transforming growth factor, beta receptor I
Thbs2 Mm01279240_m1 Mm.26688 thrombospondin 2
Timp3 Mm00441826_m1 Mm.4871 tissue inhibitor of metalloproteinase 3
Tlr1 Mm00446095_m1 Mm.273024 toll-like receptor 1
Tlr13 Mm01233819_m1 Mm.336203 toll-like receptor 13
Tlr2 Mm00442346_m1 Mm.87596 toll-like receptor 2
Tlr4 Mm00445273_m1 Mm.38049 toll-like receptor 4
Tlr7 Mm00446590_m1 Mm.23979 toll-like receptor 7
Tlr9 Mm00446193_m1 Mm.44889 toll-like receptor 9
Tmem173 Mm01158117_m1 Mm.45995 transmembrane protein 173
Tnf Mm00443258_m1 Mm.1293 tumor necrosis factor
Tnfaip3 Mm00437121_m1 Mm.116683 tumor necrosis factor, alpha-induced protein 3
Tnfrsf12a Mm01302476_g1 Mm.28518 tumor necrosis factor receptor superfamily, member 12a
Tnfrsf13b Mm00840182_m1 Mm.265915 tumor necrosis factor receptor superfamily, member 13b
Tnfrsf13c Mm00840578_g1 Mm.240047 tumor necrosis factor receptor superfamily, member 13c
Tnfrsf17 Mm00495683_m1 Mm.12935 tumor necrosis factor receptor superfamily, member 17
Tnfsf12 Mm02583406_s1 Mm.8983 tumor necrosis factor (ligand) superfamily, member 12
Tnfsf13 Mm03809849_s1 Mm.8983 tumor necrosis factor (ligand) superfamily, member 13
Tnfsf13b Mm00446347_m1 Mm.28835 tumor necrosis factor (ligand) superfamily, member 13b
Tnfsf4 Mm00437214_m1 Mm.4994 tumor necrosis factor (ligand) superfamily, member 4
Tnip1 Mm01288484_m1 Mm.259671 TNFAIP3 interacting protein 1
Tnip2 Mm00460482_m1 Mm.28615 TNFAIP3 interacting protein 2
Tnip3 Mm01181626_m1 Mm.117558 TNFAIP3 interacting protein 3
Traf1 Mm00493827_m1 Mm.239514 TNF receptor-associated factor 1
Traf2 Mm00801978_m1 Mm.3399 TNF receptor-associated factor 2
Trak1 Mm00613053_m1 Mm.491112 trafficking protein, kinesin binding 1
Trem2 Mm04209424_g1 Mm.261623 triggering receptor expressed on myeloid cells 2
Tst Mm01195231_m1 Mm.15312 thiosulfate sulfurtransferase, mitochondrial
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Txnrd2 Mm00496766_m1 Mm.390906 thioredoxin reductase 2
Tyrobp Mm00449152_m1 Mm.46301 TYRO protein tyrosine kinase binding protein
Ugt2b34 Mm00655373_m1 Mm.281844 UDP glucuronosyltransferase 2 family, polypeptide B34
Ugt2b35 Mm00655596_m1 Mm.312095 UDP glucuronosyltransferase 2 family, polypeptide B35
Umod Mm00447649_m1 Mm.10826 uromodulin
Uqcrc1 Mm00445911_m1 Mm.335460 ubiquinol-cytochrome c reductase core protein 1
Uqcrc2 Mm00445961_m1 Mm.334206 ubiquinol cytochrome c reductase core protein 2
Uqcrfs1 Mm00481849_m1 Mm.181933 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
Vamp3 Mm01268442_g1 Mm.273930 vesicle-associated membrane protein 3
Vav1 Mm01232047_m1 Mm.248172 vav 1 oncogene
Vcam1 Mm01320970_m1 Mm.440909 vascular cell adhesion molecule 1
Vegfa Mm01281449_m1 Mm.282184 vascular endothelial growth factor A
Vegfc Mm00437310_m1 Mm.1402 vascular endothelial growth factor C
Was Mm00494167_m1 Mm.4735 Wiskott-Aldrich syndrome homolog (human)
Zbtb46 Mm00511327_m1 Mm.486504 zinc finger and BTB domain containing 46
Zfp36 Mm00457144_m1 Mm.389856 zinc finger protein 36
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C4BP(β-) Assay ID UniGene ID Gene name
Chga 9,2 Mm00514341_m1 Mm.4137 chromogranin A
Pnmt 9,1 Mm00476993_m1 Mm.57030 phenylethanolamine-N-methyltransferase
Adh7 4,1 Mm00507750_m1 Mm.8473 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide
Robo1 1,1 Mm00803879_m1 Mm.310772 roundabout homolog 1 (Drosophila)
Serpina1a 1,0 Mm02748447_g1 Mm.439692 serine (or cysteine) peptidase inhibitor, clade A, member 1A
Adh1 1,0 Mm00507711_m1 Mm.2409 alcohol dehydrogenase 1 (class I)
Serpina6 1,0 Mm00432327_m1 Mm.290079 serine (or cysteine) peptidase inhibitor, clade A, member 6
Igfbp6 0,9 Mm00599696_m1 Mm.358609 insulin-like growth factor binding protein 6
Ccr6 -0,9 Mm99999114_s1 Mm.8007 chemokine (C-C motif) receptor 6
Cst7 -0,9 Mm00438349_m1 Mm.12965 cystatin F (leukocystatin)
Psmb8 -0,9 Mm01278979_m1 Mm.180191 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7)
Cd22 -0,9 Mm00515432_m1 Mm.260994 CD22 antigen
Havcr1 -0,9 Mm00506686_m1 Mm.17771 hepatitis A virus cellular receptor 1
Blk -0,9 Mm00432077_m1 Mm.3962 B lymphoid kinase
Cd3d -0,9 Mm00442746_m1 Mm.4527 CD3 antigen, delta polypeptide
Lat -1,0 Mm00456761_m1 Mm.10280 linker for activation of T cells
Tnfrsf13c -1,1 Mm00840578_g1 Mm.240047 tumor necrosis factor receptor superfamily, member 13c
Irf7 -1,2 Mm00516793_g1 Mm.3233 interferon regulatory factor 7
Prtn3 -1,3 Mm00478323_m1 Mm.2364 proteinase 3
Ms4a1 -1,4 Mm00545909_m1 Mm.4046 membrane-spanning 4-domains, subfamily A, member 1
S100a8 -1,6 Mm00496696_g1 Mm.21567 S100 calcium binding protein A8 (calgranulin A)
Cd19 -1,6 Mm00515420_m1 Mm.4360 CD19 antigen
Il12a -2,8 Mm00434165_m1 Mm.103783 interleukin 12a
Saa1 -3,4 Mm00656927_g1 Mm.148800 serum amyloid A 1
FC: Fold change
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CYP Assay ID UniGene ID Gene name
Serpina6 2,5 Mm00432327_m1 Mm.290079 serine (or cysteine) peptidase inhibitor, clade A, member 6
Serpina1d 2,1 Mm00842094_mH Mm.439695 serine (or cysteine) peptidase inhibitor, clade A, member 1D
Npy 1,7 Mm03048253_m1 Mm.154796 neuropeptide Y
Igfbp1 1,6 Mm00515154_m1 Mm.21300 insulin-like growth factor binding protein 1
C8a 1,5 Mm00521627_m1 Mm.197638 complement component 8, alpha polypeptide
Serpina1a 1,5 Mm02748447_g1 Mm.439692 serine (or cysteine) peptidase inhibitor, clade A, member 1A
Aldh6a1 1,3 Mm00506227_m1 Mm.247510 aldehyde dehydrogenase family 6, subfamily A1
Ndrg2 1,2 Mm00443481_g1 Mm.26722 N-myc downstream regulated gene 2
Ace 1,2 Mm00802048_m1 Mm.754 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
Bckdhb 1,1 Mm01177077_m1 Mm.12819 branched chain ketoacid dehydrogenase E1, beta polypeptide
Slc2a4 1,1 Mm01245502_m1 Mm.10661 solute carrier family 2 (facilitated glucose transporter), member 4
Aldh4a1 1,1 Mm00615268_m1 Mm.273571 aldehyde dehydrogenase 4 family, member A1
Plcd4 1,1 Mm00455768_m1 Mm.290731 phospholipase C, delta 4
Por 1,1 Mm00435876_m1 Mm.3863 P450 (cytochrome) oxidoreductase
Fmo1 1,1 Mm00515795_m1 Mm.976 flavin containing monooxygenase 1
Pik3c2g 1,1 Mm00440781_m1 Mm.333471 phosphatidylinositol 3-kinase, C2 domain containing, gamma 
polypeptide
Klkb1 1,0 Mm00434658_m1 Mm.482691 kallikrein B, plasma 1
Cbs 1,0 Mm00460654_m1 Mm.206417 cystathionine beta-synthase
Sod2 1,0 Mm01313000_m1 Mm.290876 superoxide dismutase 2, mitochondrial
Ugt2b34 1,0 Mm00655373_m1 Mm.281844 UDP glucuronosyltransferase 2 family, polypeptide B34
Fmo4 1,0 Mm00467393_m1 Mm.155164 flavin containing monooxygenase 4
Nox4 1,0 Mm00479246_m1 Mm.31748 NADPH oxidase 4
Ahcyl2 1,0 Mm00619649_m1 Mm.210899 S-adenosylhomocysteine hydrolase-like 2
Scd1 1,0 Mm00772290_m1 Mm.267377 stearoyl-Coenzyme A desaturase 1
Prkcz 1,0 Mm00776345_g1 Mm.28561 protein kinase C, zeta
Cat 1,0 Mm00437992_m1 Mm.4215 catalase
Adhfe1 1,0 Mm00613830_m1 Mm.28514 alcohol dehydrogenase, iron containing, 1
Serpina1d;
Serpina1b
1,0 Mm04207706_gH Mm.439692 serine (or cysteine) preptidase inhibitor, clade A, member 1B
Idh3b 0,9 Mm00504589_m1 Mm.29590 isocitrate dehydrogenase 3 (NAD+) beta
Sardh 0,9 Mm00454657_m1 Mm.278467 sarcosine dehydrogenase
Sord 0,9 Mm00455377_g1 Mm.371580 sorbitol dehydrogenase
Id1 0,9 Mm00775963_g1 Mm.444 inhibitor of DNA binding 1
Aldh9a1 0,9 Mm00480240_m1 Mm.292539 aldehyde dehydrogenase 9, subfamily A1
Sdha 0,9 Mm01352366_m1 Mm.158231 succinate dehydrogenase complex, subunit A, flavoprotein (Fp)
Bckdha 0,9 Mm00476112_m1 Mm.25848 branched chain ketoacid dehydrogenase E1, alpha polypeptide
Suox 0,9 Mm00620388_g1 Mm.23352 sulfite oxidase
Tst 0,9 Mm01195231_m1 Mm.15312 thiosulfate sulfurtransferase, mitochondrial
Pcca 0,9 Mm00454899_m1 Mm.23876 propionyl-Coenzyme A carboxylase, alpha polypeptide
Idh3g 0,9 Mm00599686_g1 Mm.14825 isocitrate dehydrogenase 3 (NAD+), gamma
Hnf4a 0,9 Mm01247712_m1 Mm.202383 hepatic nuclear factor 4, alpha
Ndufa10 0,9 Mm00600325_m1 Mm.248778 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10
Ppm1l 0,9 Mm00618786_m1 Mm.40577 protein phosphatase 1 (formerly 2C)-like
Prdx3 0,9 Mm00545848_m1 Mm.29821 peroxiredoxin 3
Got1 0,9 Mm01195792_g1 Mm.19039 glutamic-oxaloacetic transaminase 1, soluble
Ndufaf1 0,9 Mm00452828_m1 Mm.5390 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 1
Gss 0,9 Mm00515065_m1 Mm.252316 glutathione synthetase
Auh 0,9 Mm00479363_m1 Mm.252034 AU RNA binding protein/enoyl-coenzyme A hydratase
Ndufs7 0,9 Mm01144210_m1 Mm.28712 NADH dehydrogenase (ubiquinone) Fe-S protein 7
Atp5f1 0,9 Mm01296543_g1 Mm.251152 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit B1
Timp3 0,8 Mm00441826_m1 Mm.4871 tissue inhibitor of metalloproteinase 3
Aldh2 0,8 Mm00477463_m1 Mm.284446 aldehyde dehydrogenase 2, mitochondrial
Stat3 -0,9 Mm01219775_m1 Mm.249934 signal transducer and activator of transcription 3
Irf1 -0,9 Mm01288580_m1 Mm.105218 interferon regulatory factor 1
B2m -0,9 Mm00437762_m1 Mm.163 beta-2 microglobulin
Cx3cl1 -0,9 Mm00436454_m1 Mm.103711 chemokine (C-X3-C motif) ligand 1
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Ctgf -0,9 Mm01192932_g1 Mm.390287 connective tissue growth factor
Hmox1 -0,9 Mm00516005_m1 Mm.276389 heme oxygenase 1
F3 -0,9 Mm00438853_m1 Mm.273188 coagulation factor III
Tnfaip3 -0,9 Mm00437121_m1 Mm.116683 tumor necrosis factor, alpha-induced protein 3
Icam1 -0,9 Mm00516023_m1 Mm.435508 intercellular adhesion molecule 1
Tgfb1 -1,0 Mm01178820_m1 Mm.248380 transforming growth factor, beta 1
Sh3bp2 -1,0 Mm00449397_m1 Mm.5012 SH3-domain binding protein 2
Lyn -1,0 Mm01217488_m1 Mm.317331 Yamaguchi sarcoma viral (v-yes-1) oncogene homolog
Traf1 -1,0 Mm00493827_m1 Mm.239514 TNF receptor-associated factor 1
Apoe -1,0 Mm01307193_g1 Mm.305152 apolipoprotein E
Tnfsf4 -1,0 Mm00437214_m1 Mm.4994 tumor necrosis factor (ligand) superfamily, member 4
Cebpb -1,0 Mm00843434_s1 Mm.439656 CCAAT/enhancer binding protein (C/EBP), beta
Irf9 -1,0 Mm00492679_m1 Mm.2032 interferon regulatory factor 9
Inpp5d -1,0 Mm00494987_m1 Mm.15105 inositol polyphosphate-5-phosphatase D
Igfbp6 -1,0 Mm00599696_m1 Mm.358609 insulin-like growth factor binding protein 6
Cfh -1,0 Mm01299248_m1 Mm.8655 complement component factor h
Arpc1b -1,0 Mm00834862_m1 Mm.30010 actin related protein 2/3 complex, subunit 1B
C1qc -1,0 Mm00776126_m1 Mm.439732 complement component 1, q subcomponent, C chain
C4bp -1,0 Mm00432150_m1 Mm.306720 complement component 4 binding protein
Cxcr4 -1,0 Mm01996749_s1 Mm.1401 chemokine (C-X-C motif) receptor 4
C1ra -1,1 Mm04206253_g1 Mm.333375 complement component 1, r subcomponent A
Fga -1,1 Mm00802584_m1 Mm.88793 fibrinogen alpha chain
Csf1 -1,1 Mm00432686_m1 Mm.795 colony stimulating factor 1 (macrophage)
C1s1 -1,1 Mm00663210_mH Mm.219527 complement component 1, s subcomponent 1
Ikbke -1,1 Mm00444862_m1 Mm.386783 inhibitor of kappaB kinase epsilon
Map3k8 -1,2 Mm00432637_m1 Mm.3275 mitogen-activated protein kinase kinase kinase 8
Pycard -1,2 Mm00445747_g1 Mm.24163 PYD and CARD domain containing
Tlr4 -1,2 Mm00445273_m1 Mm.38049 toll-like receptor 4
Ccr1 -1,2 Mm00438260_s1 Mm.274927 chemokine (C-C motif) receptor 1
Cxcl9 -1,2 Mm00434946_m1 Mm.766 chemokine (C-X-C motif) ligand 9
Thbs2 -1,2 Mm01279240_m1 Mm.26688 thrombospondin 2
Psmb9 -1,2 Mm00479004_m1 Mm.390983 proteasome (prosome, macropain) subunit, beta type 9 (large 
multifunctional peptidase 2)
Il2rg -1,3 Mm00442885_m1 Mm.2923 interleukin 2 receptor, gamma chain
Ncf1 -1,3 Mm00447921_m1 Mm.425296 neutrophil cytosolic factor 1
Relb -1,3 Mm00485664_m1 Mm.1741 avian reticuloendotheliosis viral (v-rel) oncogene related B
Cxcl10 -1,3 Mm00445235_m1 Mm.877 chemokine (C-X-C motif) ligand 10
Mpo -1,3 Mm01298424_m1 Mm.4668 myeloperoxidase
Fgg -1,3 Mm00513575_m1 Mm.16422 fibrinogen gamma chain
Cd1d1 -1,4 Mm00783541_s1 Mm.1894 CD1d1 antigen
Ifng -1,4 Mm01168134_m1 Mm.240327 interferon gamma
Fgb -1,4 Mm00805336_m1 Mm.30063 fibrinogen beta chain
S100a8 -1,4 Mm00496696_g1 Mm.21567 S100 calcium binding protein A8 (calgranulin A)
Serping1 -1,4 Mm00437834_m1 Mm.38888 serine (or cysteine) peptidase inhibitor, clade G, member 1
Nfkbie -1,4 Mm01269649_m1 Mm.57043 nuclear factor of kappa light polypeptide gene enhancer in B cells 
inhibitor, epsilon
Tlr7 -1,4 Mm00446590_m1 Mm.23979 toll-like receptor 7
Ptpn22 -1,4 Mm00501246_m1 Mm.395 protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
Tlr1 -1,4 Mm00446095_m1 Mm.273024 toll-like receptor 1
Il33 -1,4 Mm00505403_m1 Mm.182359 interleukin 33
Nlrp3 -1,4 Mm00840904_m1 Mm.54174 NLR family, pyrin domain containing 3
Tnf -1,4 Mm00443258_m1 Mm.1293 tumor necrosis factor
Mmp9 -1,5 Mm00442991_m1 Mm.4406 matrix metallopeptidase 9
Tap1 -1,5 Mm00443188_m1 Mm.482076 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
Tnip3 -1,5 Mm01181626_m1 Mm.117558 TNFAIP3 interacting protein 3
Casp1 -1,5 Mm00438023_m1 Mm.1051 caspase 1
Prkcb -1,5 Mm00435749_m1 Mm.207496 protein kinase C, beta
Il12b -1,5 Mm00434174_m1 Mm.239707 interleukin 12b
Il27 -1,5 Mm00461162_m1 Mm.222632 interleukin 27
Ccl5 -1,5 Mm01302427_m1 Mm.284248 chemokine (C-C motif) ligand 5
Spi1 -1,5 Mm00488142_m1 Mm.1302 spleen focus forming virus (SFFV) proviral integration oncogene
Chga -1,5 Mm00514341_m1 Mm.4137 chromogranin A
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Csf2rb -1,5 Mm00655745_m1 Mm.235324 colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage)
Tyrobp -1,5 Mm00449152_m1 Mm.46301 TYRO protein tyrosine kinase binding protein
Itga4 -1,5 Mm01277951_m1 Mm.31903 integrin alpha 4
Il27ra -1,6 Mm00497259_m1 Mm.38386 interleukin 27 receptor, alpha
Cst7 -1,6 Mm00438349_m1 Mm.12965 cystatin F (leukocystatin)
Spn -1,6 Mm01164549_m1 Mm.283714 sialophorin
Ikzf1 -1,6 Mm01187882_m1 Mm.103545 IKAROS family zinc finger 1
Pik3cg -1,6 Mm00445038_m1 Mm.101369 phosphoinositide-3-kinase, catalytic, gamma polypeptide
Lck -1,6 Mm00802897_m1 Mm.293753 lymphocyte protein tyrosine kinase
Stat4 -1,6 Mm00448890_m1 Mm.1550 signal transducer and activator of transcription 4
Tlr9 -1,6 Mm00446193_m1 Mm.44889 toll-like receptor 9
Tnfsf13b -1,6 Mm00446347_m1 Mm.28835 tumor necrosis factor (ligand) superfamily, member 13b
Psmb8 -1,6 Mm01278979_m1 Mm.180191 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7)
Trem2 -1,6 Mm04209424_g1 Mm.261623 triggering receptor expressed on myeloid cells 2
Cx3cr1 -1,6 Mm02620111_s1 Mm.44065 chemokine (C-X3-C motif) receptor 1
Was -1,6 Mm00494167_m1 Mm.4735 Wiskott-Aldrich syndrome homolog (human)
Il27ra -1,6 Mm00497259_m1 Mm.38386 interleukin 27 receptor, alpha
Rac2 -1,6 Mm00485472_m1 Mm.1972 RAS-related C3 botulinum substrate 2
Cd83 -1,6 Mm00486868_m1 Mm.57175 CD83 antigen
Vav1 -1,6 Mm01232047_m1 Mm.248172 vav 1 oncogene
Btk -1,7 Mm00442712_m1 Mm.4475 Bruton agammaglobulinemia tyrosine kinase
Blk -1,7 Mm00432077_m1 Mm.3962 B lymphoid kinase
Ccr7 -1,7 Mm01301785_m1 Mm.2932 chemokine (C-C motif) receptor 7
Pdcd1lg2 -1,7 Mm00451734_m1 Mm.116737 programmed cell death 1 ligand 2
Cd22 -1,7 Mm00515432_m1 Mm.260994 CD22 antigen
Tmem173 -1,7 Mm01158117_m1 Mm.45995 transmembrane protein 173
Cd86 -1,7 Mm00444543_m1 Mm.1452 CD86 antigen
Itgb2 -1,7 Mm00434513_m1 Mm.1137 integrin beta 2
Hck -1,7 Mm01241463_m1 Mm.715 hemopoietic cell kinase
Tnfrsf12a -1,7 Mm01302476_g1 Mm.28518 tumor necrosis factor receptor superfamily, member 12a
Clec7a -1,7 Mm01183349_m1 Mm.239516 C-type lectin domain family 7, member a
Cd79b -1,7 Mm00434143_m1 Mm.2987 CD79B antigen
Icos -1,7 Mm00497600_m1 Mm.42044 inducible T cell co-stimulator
Tlr13 -1,8 Mm01233819_m1 Mm.336203 toll-like receptor 13
Fasl -1,8 Mm00438864_m1 Mm.3355 Fas ligand (TNF superfamily, member 6)
Fcer1g -1,8 Mm02343757_m1 Mm.22673 Fc receptor, IgE, high affinity I, gamma polypeptide
Aim2 -1,8 Mm01295719_m1 Mm.131453 absent in melanoma 2
Pld4 -1,8 Mm00626861_m1 Mm.203915 phospholipase D family, member 4
C1qa -1,8 Mm00432142_m1 Mm.439957 complement component 1, q subcomponent, alpha polypeptide
Cd276 -1,8 Mm00506020_m1 Mm.5356 CD276 antigen
Tnfrsf13b -1,8 Mm00840182_m1 Mm.265915 tumor necrosis factor receptor superfamily, member 13b
Osmr -1,8 Mm01307326_m1 Mm.10760 oncostatin M receptor
Cd74 -1,8 Mm00658576_m1 Mm.439737 CD74 antigen (invariant polypeptide of major histocompatibility 
complex, class II antigen-associated)
Prtn3 -1,8 Mm00478323_m1 Mm.2364 proteinase 3
Syk -1,8 Mm01333032_m1 Mm.375031 spleen tyrosine kinase
Cd48 -1,9 Mm00455932_m1 Mm.1738 CD48 antigen
Il10ra -1,9 Mm00434151_m1 Mm.379327 interleukin 10 receptor, alpha
Cxcl1 -1,9 Mm04207460_m1 Mm.21013 chemokine (C-X-C motif) ligand 1
Irf7 -1,9 Mm00516793_g1 Mm.3233 interferon regulatory factor 7
Clec10a -1,9 Mm00546125_g1 Mm.252405 C-type lectin domain family 10, member A
C3ar1 -1,9 Mm02620006_s1 Mm.2408 complement component 3a receptor 1
C1qb -1,9 Mm01179619_m1 Mm.2570 complement component 1, q subcomponent, beta polypeptide
Fcgr3 -1,9 Mm00438882_m1 Mm.22119 Fc receptor, IgG, low affinity III
Cd3g -1,9 Mm00438095_m1 Mm.335106 CD3 antigen, gamma polypeptide
Clu -1,9 Mm01197002_m1 Mm.200608 clusterin
Ltb -2,0 Mm00434774_g1 Mm.1715 lymphotoxin B
Lcp2 -2,0 Mm01187570_m1 Mm.265350 lymphocyte cytosolic protein 2
Ifi202b -2,0 Mm00839397_m1 Mm.218770 interferon activated gene 202B
Lat -2,0 Mm00456761_m1 Mm.10280 linker for activation of T cells
Vcam1 -2,0 Mm01320970_m1 Mm.440909 vascular cell adhesion molecule 1
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Il1r2 -2,0 Mm00439629_m1 Mm.1349 interleukin 1 receptor, type II
Pik3r5 -2,0 Mm00805206_m1 Mm.244960 phosphoinositide-3-kinase, regulatory subunit 5, p101
Ptprc -2,0 Mm01293577_m1 Mm.391573 protein tyrosine phosphatase, receptor type, C
Spp1 -2,0 Mm00436767_m1 Mm.288474 secreted phosphoprotein 1
Ccr2 -2,0 Mm00438270_m1 Mm.6272 chemokine (C-C motif) receptor 2
Col1a2 -2,1 Mm00483888_m1 Mm.277792 collagen, type I, alpha 2
Fn1 -2,1 Mm01256744_m1 Mm.193099 fibronectin 1
Cd80 -2,1 Mm00711660_m1 Mm.89474 CD80 antigen
Foxp3 -2,1 Mm00475162_m1 Mm.182291 forkhead box P3
Cd40lg -2,1 Mm00441911_m1 Mm.4861 CD40 ligand
Clec4n -2,2 Mm00490934_m1 Mm.271782 C-type lectin domain family 4, member n
Pnmt -2,2 Mm00476993_m1 Mm.57030 phenylethanolamine-N-methyltransferase
Ctla4 -2,2 Mm00486849_m1 Mm.390 cytotoxic T-lymphocyte-associated protein 4
Msr1 -2,2 Mm00446214_m1 Mm.239291 macrophage scavenger receptor 1
Il1b -2,2 Mm00434228_m1 Mm.222830 interleukin 1 beta
Cd28 -2,2 Mm00483137_m1 Mm.255003 CD28 antigen
Ccr6 -2,2 Mm99999114_s1 Mm.8007 chemokine (C-C motif) receptor 6
Cd3d -2,3 Mm00442746_m1 Mm.4527 CD3 antigen, delta polypeptide
Il10 -2,3 Mm00439614_m1 Mm.874 interleukin 10
Gpnmb -2,3 Mm01328587_m1 Mm.302602 glycoprotein (transmembrane) nmb
Serpine1 -2,3 Mm00435860_m1 Mm.250422 serine (or cysteine) peptidase inhibitor, clade E, member 1
Ctss -2,3 Mm01255859_m1 Mm.3619 cathepsin S
Ccl9 -2,3 Mm00441260_m1 Mm.416125 chemokine (C-C motif) ligand 9
Cd19 -2,3 Mm00515420_m1 Mm.4360 CD19 antigen
Cd300lb -2,3 Mm01701741_m1 Mm.185355 CD300 antigen like family member B
Fcgr4 -2,3 Mm00519988_m1 Mm.251254 Fc receptor, IgG, low affinity IV
Cd5 -2,4 Mm00432417_m1 Mm.779 CD5 antigen
Tnfrsf17 -2,4 Mm00495683_m1 Mm.12935 tumor necrosis factor receptor superfamily, member 17
Tnfrsf13c -2,4 Mm00840578_g1 Mm.240047 tumor necrosis factor receptor superfamily, member 13c
Irf4 -2,4 Mm00516431_m1 Mm.4677 interferon regulatory factor 4
Fcgr1 -2,4 Mm00438874_m1 Mm.150 Fc receptor, IgG, high affinity I
Ccl2 -2,4 Mm00441242_m1 Mm.290320 chemokine (C-C motif) ligand 2
Ms4a1 -2,5 Mm00545909_m1 Mm.4046 membrane-spanning 4-domains, subfamily A, member 1
Havcr1 -2,5 Mm00506686_m1 Mm.17771 hepatitis A virus cellular receptor 1
Cd14 -2,5 Mm00438094_g1 Mm.3460 CD14 antigen
Itgam -2,5 Mm00434455_m1 Mm.262106 integrin alpha M
Il7r -2,6 Mm00434295_m1 Mm.389 interleukin 7 receptor
C3 -2,7 Mm00437838_m1 Mm.19131 complement component 3
Cxcl2 -2,7 Mm00436450_m1 Mm.4979 chemokine (C-X-C motif) ligand 2
Ereg -2,7 Mm00514794_m1 Mm.4791 epiregulin
Il17a -2,7 Mm00439618_m1 Mm.5419 interleukin 17A
Col3a1 -2,7 Mm01254476_m1 Mm.249555 collagen, type III, alpha 1
Ccr5 -2,7 Mm01963251_s1 Mm.14302 chemokine (C-C motif) receptor 5
Socs3 -2,8 Mm00545913_s1 Mm.3468 suppressor of cytokine signaling 3
C6 -2,8 Mm00489521_m1 Mm.20247 complement component 6
Col1a1 -3,0 Mm00801666_g1 Mm.277735 collagen, type I, alpha 1
Cxcl13 -3,1 Mm04214185_s1 Mm.10116 chemokine (C-X-C motif) ligand 13
Saa1 -4,5 Mm00656927_g1 Mm.148800 serum amyloid A 1
Il1f6 -6,0 Mm00457645_m1 Mm.133095 interleukin 1 family, member 6
FC: Fold change
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Table S4.- Relevant enriched biological functions (IPA®) associated with 
differentially expressed renal genes from C4BP(β-)-treated NZBW F1 mice.
 





Quantity of leukocytes 14 2,91x10-11 -2,836
Activation of leukocytes 10 6,03x10-10 -1,455
Quantity of mononuclear 
leukocytes 12 6,06x10-10 -2,541
Quantity of lymphocytes 11 6,87x10-9 -2,839
Leukocyte migration 9 8,12x10-7 -1,966
Activation of lymphocytes 6 5,71x10-6 -1,368
Quantity of B lymphocytes 6 1,41x10-5 -2,223
Cell viability of lymphocytes 4 4,15x10-5 -1,969
Cell movement of phagocytes 5 3,53x10-4 -2,211
Cell movement of myeloid cells 5 3,59x10-4 -2,195
Cellular infiltration by leukocytes 4 1,90x10-3 -1,972
Inflammation of organ 5 7,56x10-3  0,753
*Activation z-score is calculated by the IPA software and predicts whether a specific disease or bio-
function is increased (positive z-score) or decreased (negative z-score) based on the experimental 
dataset. In bold are significant Bio-functions with z-score >2 or < -2. 
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